

## Author Search

⇒ FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 12:51:04 ON 18 NOV 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21  
 FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

⇒ D STAT QUE L45

L6	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)-"/CN
L8	1204	SEA FILE=REGISTRY ABB=ON	PLU=ON	77-86-1/CRN
L9	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-B,Δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,ΔR)-"/CN
L10	131	SEA FILE=REGISTRY ABB=ON	PLU=ON	134523-00-5/CRN
L12	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	"PROPANOIC ACID, 2-(4-(4-CHLORO BENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
L13	17	SEA FILE=REGISTRY ABB=ON	PLU=ON	49562-28-9/CRN
L14	10674	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L6 OR L8)
L15	4140	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L9 OR L10)
L16	1868	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L12 OR L13)
L17	9	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L14 AND L15 AND L16
L28	406	SEA FILE=HCAPLUS ABB=ON	PLU=ON	HOLM P?/AU
L29	32	SEA FILE=HCAPLUS ABB=ON	PLU=ON	NORLING T?/AU
L30	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L28 OR L29) AND L17
L44	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L28 OR L29) AND L17
L45	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L30 OR L44)

Serial No.:10/582,410

⇒ FILE BIOSIS EMBASE MEDLINE TOXCENTER DRUGU  
FILE 'BIOSIS' ENTERED AT 12:51:45 ON 18 NOV 2008  
Copyright I 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:51:45 ON 18 NOV 2008  
Copyright I 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:51:45 ON 18 NOV 2008

FILE 'TOXCENTER' ENTERED AT 12:51:45 ON 18 NOV 2008  
COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 12:51:45 ON 18 NOV 2008  
COPYRIGHT I 2008 THOMSON REUTERS

⇒ D STAT QUE L31

L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1,3-PROPANEDIOL, 2-AMINO-2-(  
HYDROXYMETHYL)-"/CN  
L8 1204 SEA FILE=REGISTRY ABB=ON PLU=ON 77-86-1/CRN  
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1H-PYRROLE-1-HEPTANOIC  
ACID, 2-(4-FLUOROPHENYL)-B,Δ-DIHYDROXY-5-(1-METHYLET  
HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR,ΔR)-"/  
CN  
L10 131 SEA FILE=REGISTRY ABB=ON PLU=ON 134523-00-5/CRN  
L12 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PROPANOIC ACID, 2-(4-(4-CHLO  
ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN  
L13 17 SEA FILE=REGISTRY ABB=ON PLU=ON 49562-28-9/CRN  
L19 12476 SEA (L6 OR L8)  
L20 18785 SEA (L9 OR L10)  
L21 9094 SEA (L12 OR L13)  
L22 8 SEA L19 AND L20 AND L21  
L28 406 SEA FILE=HCAPLUS ABB=ON PLU=ON HOLM P?/AU  
L29 32 SEA FILE=HCAPLUS ABB=ON PLU=ON NORLING T?/AU  
L31 0 SEA (L28 OR L29) AND L22

⇒ DUP REM L45 L31

L31 HAS NO ANSWERS

FILE 'HCAPLUS' ENTERED AT 12:52:12 ON 18 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT I 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21  
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

PROCESSING COMPLETED FOR L45

PROCESSING COMPLETED FOR L31

L51 1 DUP REM L45 L31 (0 DUPLICATES REMOVED)

ANSWER '1' FROM FILE HCAPLUS

⇒ D IBIB ED ABS HITSTR L51 1

L51 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:818282 HCAPLUS Full-text

DOCUMENT NUMBER: 145:235854

TITLE: A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor

INVENTOR(S): Holm, Per; Norling, Tomas

PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084474	A2	20060817	WO 2006-DK50004	20060210
WO 2006084474	A3	20061102		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006212609	A1	20060817	AU 2006-212609	20060210
CA 2597492	A1	20060817	CA 2006-2597492	20060210
EP 1853249	A2	20071114	EP 2006-706137	20060210
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
US 20080131503	A1	20080605	US 2006-582410	20060919
MX 200709281	A	20070925	MX 2007-9281	20070801
CN 101115478	A	20080130	CN 2006-80004608	20070810
KR 2007104447	A	20071025	KR 2007-719786	20070830
IN 2007CN03914	A	20071221	IN 2007-CN3914	20070910
PRIORITY APPLN. INFO.:			DK 2005-200	A 20050210
			DK 2005-576	A 20050420
			WO 2006-DK50004	W 20060210


ED Entered STN: 17 Aug 2006

AB A pharmaceutical composition for oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first and the second pharmaceutical compns. Are present in sep. entities in a single solid dosage form. For example a multilayer tablet, a two-layer tablet, or capsules or sachets contain the active ingredients in sep. granulates or beads, either granulate or bead optionally being coated with a protective coating or an entero-coating. Thus, a two-layer tablet was prepared comprising (i) fenofibrate granulate containing fenofibrate 145, PEG6000 189, Poloxamer 188 81, lactose 339, and Mg stearate 7.6, and (ii) atorvastatin granulate containing atorvastatin magnesium 44, mannitol 122, Mg stearate 1.5, Klucel 7, Polysorbate 80 2.4, Avicel 119, and trometamol 2.5 mg, resp. The resulting tablet had a weight of about 1060 mg.

IT 77-86-1 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (stable oral compns. Comprising fixed dose combination of fenofibrate and HMG-CoA reductase inhibitor)


RN 77-86-1 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

Serial No.:10/582,410

## Structure Search

=> FILE HCAPLUS  
FILE 'HCAPLUS' ENTERED AT 12:52:28 ON 18 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21  
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.  
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L17  
L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)-"/CN  
L8 1204 SEA FILE=REGISTRY ABB=ON PLU=ON 77-86-1/CRN  
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-B, $\Delta$ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR, $\Delta$ )-"/CN  
L10 131 SEA FILE=REGISTRY ABB=ON PLU=ON 134523-00-5/CRN  
L12 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PROPANOIC ACID, 2-(4-(4-CHLORO BENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN  
L13 17 SEA FILE=REGISTRY ABB=ON PLU=ON 49562-28-9/CRN  
L14 10674 SEA FILE=HCAPLUS ABB=ON PLU=ON (L6 OR L8)  
L15 4140 SEA FILE=HCAPLUS ABB=ON PLU=ON (L9 OR L10)  
L16 1868 SEA FILE=HCAPLUS ABB=ON PLU=ON (L12 OR L13)  
L17 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L15 AND L16

=> S L17 NOT L45  
L52 8 L17 NOT L45

=> FILE BIOSIS EMBASE MEDLINE TOXCENTER DRUGU  
FILE 'BIOSIS' ENTERED AT 12:52:55 ON 18 NOV 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:52:55 ON 18 NOV 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

Serial No.:10/582,410

FILE 'MEDLINE' ENTERED AT 12:52:55 ON 18 NOV 2008

FILE 'TOXCENTER' ENTERED AT 12:52:55 ON 18 NOV 2008  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 12:52:55 ON 18 NOV 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

=> D STAT QUE L22

L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1,3-PROPANEDIOL, 2-AMINO-2-(  
HYDROXYMETHYL)-"/CN  
L8 1204 SEA FILE=REGISTRY ABB=ON PLU=ON 77-86-1/CRN  
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "1H-PYRROLE-1-HEPTANOIC  
ACID, 2-(4-FLUOROPHENYL)-B, $\Delta$ -DIHYDROXY-5-(1-METHYLET  
HYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (BR, $\Delta$ R)-"/  
CN  
L10 131 SEA FILE=REGISTRY ABB=ON PLU=ON 134523-00-5/CRN  
L12 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PROPANOIC ACID, 2-(4-(4-CHLO  
ROBENZOYL)PHENOXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN  
L13 17 SEA FILE=REGISTRY ABB=ON PLU=ON 49562-28-9/CRN  
L19 12476 SEA (L6 OR L8)  
L20 18785 SEA (L9 OR L10)  
L21 9094 SEA (L12 OR L13)  
L22 8 SEA L19 AND L20 AND L21

=> S L22 NOT L31

L53 8 L22 NOT L31

=> DUP REM L52 L53

FILE 'HCAPLUS' ENTERED AT 12:53:19 ON 18 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 12:53:19 ON 18 NOV 2008  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L52  
PROCESSING COMPLETED FOR L53

L54 9 DUP REM L52 L53 (7 DUPLICATES REMOVED)  
ANSWERS '1-8' FROM FILE HCAPLUS  
ANSWER '9' FROM FILE TOXCENTER

=> D IBIB ED ABS HITSTR L54 1-8; D IALL 9 L54

L54 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2008:974067 HCAPLUS Full-text

DOCUMENT NUMBER: 149:267913

TITLE: Preparation of quinoline compounds as modulators of  
TGR5 for treatment of disease

INVENTOR(S): Pinkerton, Anthony B.; Kabakibi, Ayman; Herbert, Mark  
R.; Siegel, Dana L.

PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: PCT Int. Appl., 186pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008097976	A1	20080814	WO 2008-US53056	20080205
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080221161	A1	20080911	US 2008-26315	20080205
PRIORITY APPLN. INFO.:			US 2007-889181P	P 20070209
			US 2007-957516P	P 20070823
OTHER SOURCE(S): MARPAT 149:267913				
ED Entered STN: 14 Aug 2008				
GI				



I




II

AB Disclosed herein are compds. of general formula I (wherein X is (CR<sup>9</sup>R<sup>10</sup>)<sub>m</sub>; Y is (CR<sup>11</sup>R<sup>12</sup>)<sub>n</sub>, etc.; m=0-2; n=0-3; R<sup>1</sup> is aryl, heteroaryl, etc.; R<sup>2</sup> is H, lower alkyl, etc.; R<sup>3</sup> is H, amino, alkyl, etc.; R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are independently H, halo, OH, etc.; R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup> are independently H, lower alkyl, etc.) useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 7-methoxy-2-(thiophen-3-yl)quinoline-3- carboxaldehyde with (4-trifluoromethylphenyl)methanamine. In an assay measuring cAMP production by HEK293 cells expressing TGR5, II had an EC<sub>50</sub> > 10μM.

IT 1185-53-1 49562-28-9 134523-00-5  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (codrug; preparation of quinoline compds. as modulators of TGR5 for treatment of disease)


RN 1185-53-1 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2008:673110 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 149:32334

TITLE: Preparation of diazepines and other heterocyclic modulators of TGR5 for treating metabolic, cardiovascular, and inflammatory diseases

INVENTOR(S): Pinkerton, Anthony B.; Kabakibi, Ayman; Gahman, Timothy C.

PATENT ASSIGNEE(S): Kalypsys, Inc., USA

SOURCE: PCT Int. Appl., 123pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008067222	A1	20080605	WO 2007-US85267	20071120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

US 2006-867583P


P 20061128

OTHER SOURCE(S):

MARPAT 149:32334

ED Entered STN: 06 Jun 2008

GI



AB The present invention relates to heterocyclic compds. of general formula I (wherein A is a 5-6-membered monocyclic heterocycloalkyl ring; X is O, S, etc.; Y is substituted N or C; Q1 and Q2 are N or substituted C; n is 0-2; R1 and R2 are independently null, acyl, alkyl, etc.; R3 is aryl, heteroaryl, etc.; R4 is a bond, H, halo, etc.; R5, R6, R7, R8 are independently H, alkyl, etc.) useful as modulators of TGR5 and methods for the treatment of prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 3,5-Bis(trifluoromethylphenylcarbonyl) chloride with 1-phenyl-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepine hydrochloride (preparation given). In an assay that measured cAMP production by HEK-293 cells transfected with TGR5, II had an EC50 of  $\leq 10 \mu\text{M}$ .

IT 1185-53-1, T 6666 49562-28-9, Fenofibrate

134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(codrug; preparation of diazepines and other heterocyclic modulators of

TGR5

for treating metabolic, cardiovascular, and inflammatory diseases)


RN 1185-53-1 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2008:191482 HCAPLUS Full-text

DOCUMENT NUMBER: 148:246490

TITLE: Conveniently implantable sustained release drug compositions

# Serial No.:10/582,410

INVENTOR(S): Wong, Vernon G.; Wood, Louis L.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 54pp., Cont.-in-part of U.S. Ser. No. 236,426.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080038316	A1	20080214	US 2007-826833	20070718
US 20060073182	A1	20060406	US 2005-236426	20050927
AU 2005292145	A1	20060413	AU 2005-292145	20050927
CA 2582096	A1	20060413	CA 2005-2582096	20050927
EP 1793803	A2	20070613	EP 2005-804034	20050927
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101060831	A	20071024	CN 2005-80039775	20050927
JP 2008514719	T	20080508	JP 2007-534731	20050927
BR 2005016830	A	20080923	BR 2005-16830	20050927
MX 200703968	A	20080304	MX 2007-3968	20070402
IN 2007MN00515	A	20070803	IN 2007-MN515	20070409
KR 2007083901	A	20070824	KR 2007-709976	20070501
PRIORITY APPLN. INFO.:			US 2004-614484P	P 20041001
			US 2005-709665P	P 20050819
			US 2005-236426	A2 20050927
			US 2006-831991P	P 20060719
			WO 2005-US34822	W 20050927

OTHER SOURCE(S): CASREACT 148:246490

ED Entered STN: 15 Feb 2008


AB This invention provides biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states. Thus, 760 mg of tri-Et O-acetyl citrate (TEAC) was mixed with 240 mg of dexamethasone (Dex) and 6 mg (25 µL) and 12 mg (25 µL) microdrops of this mixture were each incubated in 10 mL of 0.9% saline at 37°. A sustained release of dexamethasone from a formulation consisting of 24% Dex in TEAC was observed. However, adding tocopherol acetate to the TEAC excipient at the ratio of 1:1 can extend the sustained release of therapeutic levels of Dex up to 450 days.

IT 49562-28-9, Fenofibrate 74103-67-4, Ketorolac tromethamine 134523-00-5, Atorvastatin

RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (injectable biocompatible and biodegradable implantable sustained release drug compns.)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 74103-07-4 HCAPLUS

CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with  
2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 74103-06-3


CMF C15 H13 N O3



CM 2

CRN 77-86-1


CMF C4 H11 N O3



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



## Serial No.:10/582,410

DOCUMENT NUMBER: 146:82189  
 TITLE: Preparation of L-threonine derivatives with high therapeutic index  
 INVENTOR(S): Chandran, V. Ravi  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 60pp., Cont.-in-part of U.S. Ser. No. 343,557.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060287244	A1	20061221	US 2006-442027	20060526
WO 2005046575	A2	20050526	WO 2004-US24901	20040729
WO 2005046575	A3	20071004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

US 20060241017	A1	20061026	US 2006-343557	20060130
PRIORITY APPLN. INFO.:			US 2003-491331P	P 20030729
			WO 2004-US24901	A2 20040729
			US 2006-343557	A2 20060130

OTHER SOURCE(S): CASREACT 146:82189

ED Entered STN: 22 Dec 2006

AB The invention is directed to novel therapeutic compds. comprised of an L-threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating function. These high-therapeutic index derivs. have the same utility as the drug from which they are made and they have enhanced pharmacol. and pharmaceutical properties, with the addnl. advantage of separating various enantiomeric and diastereomeric drugs into their individual isomers. The examples describe the synthesis and activities of L-threonine derivs. of (±)- and (+)-(S)-ibuprofen, (±)- and (+)-(S)-ketoprofen, (-)-(S)-ketorolac, aspirin, and fenofibric acid. The synthesis and activity of several L-serine and L-hydroxyproline analogs were also described. Thus, the hydrochloride of (+)-(S)-ibuprofen ester of L-threonine was prepared, and its free base examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.

IT 917472-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of L-threonine derivs. with high therapeutic index)

RN 917472-08-3 HCAPLUS


CN L-Threonine, ester with (βR,δR)-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (CA INDEX NAME)

CM 1

Serial No.:10/582,410

CRN 134523-00-5  
CMF C33 H35 F N2 O5


Absolute stereochemistry.




CM 2

CRN 72-19-5  
CMF C4 H9 N O3

Absolute stereochemistry.




IT 49562-28-9, Fenofibrate 74103-07-4 134523-00-5  
, Atorvastatin  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of L-threonine derivs. with high therapeutic index)  
RN 49562-28-9 HCAPLUS  
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
ester (CA INDEX NAME)



RN 74103-07-4 HCAPLUS  
CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with  
2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1


CRN 74103-06-3  
CMF C15 H13 N O3



CM 2

CRN 77-86-1


CMF C4 H11 N O3



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta,\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2006:1124123 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:455276

TITLE: Preparation of amino acid derivatives with high therapeutic index

INVENTOR(S): Chandran, V. Ravi

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 139pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060241017	A1	20061026	US 2006-343557	20060130
WO 2005046575	A2	20050526	WO 2004-US24901	20040729
WO 2005046575	A3	20071004		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
US 20060287244	A1	20061221	US 2006-442027	20060526
WO 2007089745	A2	20070809	WO 2007-US2475	20070129
WO 2007089745	A3	20080821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			US 2003-491331P	P 20030729
			WO 2004-US24901	A2 20040729
			US 2006-343557	A2 20060130
ED	Entered STN: 27 Oct 2006			
AB	The invention is directed to novel therapeutic compds. comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating function. These high-therapeutic index derivs. have the same utility as the drug from which they are made and they have enhanced pharmacol. and pharmaceutical properties. The examples describe the synthesis and activities of amino acid derivs. of propofol, ibuprofen, ketoprofen, ketorolac, aspirin, acetaminophen, cyclosporin A, valproic acid, clopidogrel, damazol, benzapril, enalapril, and fenofibric acid. Thus, (±)-ibuprofen esters of L-serine, L-threonine, and L-hydroxyproline were prepared and examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.			
IT	74103-07-4			
	RL: RCT (Reactant); RACT (Reactant or reagent)			
	(preparation of amino acid derivs. with high therapeutic index)			
RN	74103-07-4 HCAPLUS			
CN	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)			
CM	1			
CRN	74103-06-3			
CMF	C15 H13 N O3			




CM 2

CRN 77-86-1

CMF C4 H11 N O3




IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT  
 (Reactant or reagent); USES (Uses)  
 (preparation of amino acid derivs. with high therapeutic index)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-  
 (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-  
 (CA INDEX NAME)

Absolute stereochemistry.



L54 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7  
 ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text  
 DOCUMENT NUMBER: 144:198849  
 TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients  
 INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar  
 PATENT ASSIGNEE(S): India  
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

ED Entered STN: 03 Feb 2006


AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 77-86-1, Trometamol 49562-28-9, Fenofibrate  
 109636-76-2, Prinomide tromethamine 134523-03-8,  
 Atorvastatin calcium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel dosage form comprising modified-release and immediate-release active ingredients)


RN 77-86-1 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 109636-76-2 HCAPLUS

CN 1H-Pyrrole-2-propanamide,  $\alpha$ -cyano-1-methyl- $\beta$ -oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8


CMF C15 H13 N3 O2



CM 2

CRN 77-86-1


CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

L54 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:769872 HCAPLUS Full-text

DOCUMENT NUMBER: 148:387155

TITLE: Novel dosage form

INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar

PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India

SOURCE: Indian Pat. Appl., 96pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826
PRIORITY APPLN. INFO.:			IN 2005-MU1013	20050826

ED Entered STN: 17 Jul 2007

AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.


IT 77-86-1, Trometamol 49562-28-9, Fenofibrate  
109636-76-2, Prinomide Tromethamine 134523-03-8,  
Atorvastatin Calcium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel dosage form containing modified-release and immediate-release active ingredients)

RN 77-86-1 HCAPLUS


CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

Serial No.:10/582,410

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 109636-76-2 HCAPLUS

CN 1H-Pyrrole-2-propanamide,  $\alpha$ -cyano-1-methyl- $\beta$ -oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8


CMF C15 H13 N3 O2



CM 2

CRN 77-86-1


CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

L54 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1016569 HCAPLUS Full-text  
 DOCUMENT NUMBER: 148:503081  
 TITLE: Novel drug delivery system  
 INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh  
 Singh; Gupta, Vinod Kumar  
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India  
 SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No.  
 2004MU198.  
 CODEN: INXXBQ  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198	A0 20040220

ED Entered STN: 12 Sep 2007


AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

IT 77-86-1, Trometamol 49562-28-9, Fenofibrate  
 109636-76-2, Prinomide Tromethamine 134523-03-8,  
 Atorvastatin Calcium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel drug delivery system)

RN 77-86-1 HCAPLUS


CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

Serial No.:10/582,410

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 109636-76-2 HCAPLUS

CN 1H-Pyrrole-2-propanamide,  $\alpha$ -cyano-1-methyl- $\beta$ -oxo-N-phenyl-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 77639-66-8


CMF C15 H13 N3 O2



CM 2

CRN 77-86-1


CMF C4 H11 N O3



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

L54 ANSWER 9 OF 9 TOXCENTER COPYRIGHT 2008 ACS on STN DUPLICATE 4  
 ACCESSION NUMBER: 2008:54819 TOXCENTER Full-text  
 COPYRIGHT: Copyright 2008 ACS  
 DOCUMENT NUMBER: CA14822503081E  
 TITLE: Novel drug delivery system  
 AUTHOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh  
 Singh; Gupta, Vinod Kumar  
 CORPORATE SOURCE: ASSIGNEE: Torrent Pharmaceuticals Limited  
 PATENT INFORMATION: IN 2005MU01012 A 31 Aug 2007  
 SOURCE: (2007) Indian Pat. Appl., 80pp., Addn. of Indian Appl. No.  
 2004MU198.  
 CODEN: INXXBQ.  
 COUNTRY: INDIA  
 DOCUMENT TYPE: Patent  
 FILE SEGMENT: CAPLUS  
 OTHER SOURCE: CAPLUS 2007:1016569  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 19 Feb 2008  
 Last Updated on STN: 29 Jul 2008

ABSTRACT:

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

CLASSIFICATION CODE: 63-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors  
 metformin niacin venlafaxine valproate tablet dissoln drug  
 bioavailability

REGISTRY NUMBER: 404-86-4Q (Capsaicin, analogs)  
 13408-29-2 (Nitroxide)  
 70-18-8 (Glutathione)  
 9013-05-2 (Phosphatase)  
 9040-48-6 (Gelatinase)  
 79955-99-0 (Stromelysin 1)  
 120178-12-3 (Telomerase)  
 141256-52-2 (Matrilysin)  
 67-64-1 (Acetone)  
 75-09-2 (Methylene chloride)  
 1115-70-4 (Metformin hydrochloride)

Serial No.:10/582,410

50-78-2	(Aspirin)
REGISTRY NUMBER:	35425-83-3 (Quinuclidium Bromide)
	35449-36-6 (Gemcadiol)
	35523-45-6 (Fludalanine)
	35554-44-0 (Enilconazole)
	35578-20-2 (Oxarbazole)
	35604-67-2 (Viloxazine Hydrochloride)
	35607-20-6 (Avridine)
	35607-66-0 (Cefoxitin)
	35700-23-3 (Carboprost)
	35764-29-5 (Fluotracen Hydrochloride)
	35795-17-6 (Trimazosin Hydrochloride)
	35834-26-5 (Rosaramicin)
	35838-58-5 (Etazolate Hydrochloride)
	35846-53-8 (Maitansine)
	35941-71-0 (Tiaramide Hydrochloride)
	35943-35-2 (Triciribine)
	36167-63-2 (Halofantrine Hydrochloride)
	36282-47-0 (Tramadol hydrochloride)
	36292-69-0 (Ketazocine)
	36322-90-4 (Piroxicam)
	36330-85-5 (Fenbufen)
	36504-94-6 (Butaclamol Hydrochloride)
	36505-82-5 (Prodolic Acid)
	36508-71-1 (Zorubicin Hydrochloride)
	36616-52-1 (Fenclorac)
	36637-18-0 (Etidocaine)
	36653-82-4 (Cetyl alcohol)
	36735-22-5 (Quazepam)
	36740-73-5 (Flumizole)
	36791-04-5 (Ribavirin)
	36945-03-6 (Lergotrile)
	36950-96-6 (Cicloprofen)
	36981-91-6 (Fepradinol)
	36983-69-4 (Actodigin)
	36983-81-0 (Fosfonet Sodium)
	37087-94-8 (Tibric Acid)
	37091-66-0 (Azlocillin)
	37106-97-1 (Bentiromide)
	37115-32-5 (Adinazolam)
	37200-12-7 (Poly(isodecyl methacrylate))
	37270-89-6 (Nadroparin calcium)
	37321-09-8 (Apramycin)
	37332-99-3 (Avoparcin)
	37517-26-3 (Pipotiazine Palmitate)
	37517-30-9 (Acebutolol)
	37554-40-8 (Fluquazone)
	37640-71-4 (Aprindine)
	37661-08-8 (Bacampicillin Hydrochloride)
	37686-84-3 (Terguride)
	37717-21-8 (Flurocitabine)
	37723-78-7 (Iopronic Acid)
	37750-83-7 (Rimoprogin)
	37751-39-6 (Ciclazindol)
	37800-79-6 (Difenoximide Hydrochloride)
	37863-70-0 (Iosumetic Acid)
	38070-41-6 (Tiodonium Chloride)
	38081-67-3 (Carmantadine)
	38103-61-6 (Tolamolol)
	38194-50-2 (Sulindac)

Serial No.:10/582,410

38241-28-0 (Zinterol Hydrochloride)  
38241-39-3 (Tazolol Hydrochloride)  
38270-90-5Q (Strontium chloride (89SrCl<sub>2</sub>), Sr 89)  
38274-54-3 (Benurestat)  
38304-91-5 (Minoxidil)  
38363-32-5 (Penbutolol Sulfate)  
38677-85-9 (Flunixin)  
38821-53-3 (Cephhradine)  
38821-80-6 (Rodocaine)  
38873-55-1 (Furobufen)  
38955-22-5 (Pinadoline)  
39022-39-4 (Oxaprotiline Hydrochloride)  
39186-49-7 (Pirolazamide)  
39236-46-9 (Imidurea)  
39294-79-6 (Seractide Acetate)  
39324-30-6 (Pepstatin)  
39325-01-4 (Picibanil)  
39562-70-4 (Nitrendipine)  
39624-65-2 (Azanator Maleate)  
39624-66-3 (Trepipam Maleate)  
39698-78-7 (Saralasin Acetate)  
39791-20-3 (Nylestriol)  
39809-25-1 (Penciclovir)  
39878-70-1 (Talampicillin Hydrochloride)  
40034-42-2 (Rosoxacin)  
40054-69-1 (Etizolam)  
40180-04-9 (Ticrynafen)  
40391-99-9 (Pamidronic acid)  
40507-23-1 (Fluproquazone)  
40594-09-0 (Flucindole)  
40691-50-7 (Tixanox)  
40759-33-9 (Nolinium Bromide)  
40796-97-2 (Bemesetron)  
40819-93-0 (Lorajmine Hydrochloride)  
40828-44-2 (Clazolimine)  
40828-45-3 (Azolimine)  
40828-46-4 (Suprofen)  
40966-79-8 (Sarpicillin)  
41020-67-1 (Mexrenoate Potassium)  
41020-79-5 (Dicirenone)  
41078-02-8 (Enprofylline)  
41094-88-6 (Tracazolate)  
41113-86-4 (Bromoxanide)  
41147-04-0 (Xanoxate Sodium)  
41294-56-8 (Alfacalcidol)  
41340-25-4 (Etodolac)  
41570-61-0 (Tulobuterol)  
41575-94-4 (Carboplatin)  
41708-72-9 (Tocainide)  
41767-29-7 (Fluocortin Butyl)  
41859-67-0 (Bezafibrate)  
41964-07-2 (Tolimidone)  
41992-22-7 (Spirogermanium Hydrochloride)  
42045-97-6 (Phenaridine)  
42116-76-7 (Carnidazole)  
42200-33-9 (Nadolol)  
42220-21-3 (Iodocholesterol I 131)  
42228-92-2 (Acivicin)  
42281-59-4 (Oxilorphan)  
42408-78-6 (Pirandamine Hydrochloride)

Serial No.:10/582,410

42408-82-2 (Butorphanol)  
42422-68-4 (Taleranol)  
42461-78-9 (Sulfontolol Hydrochloride)  
42616-25-1 (Methioninase)  
42779-82-8 (Clopirac)  
42794-76-3 (Midodrine)  
42835-25-6 (Flumequine)  
42864-78-8 (Bevantolol Hydrochloride)  
42877-18-9 (Pelanserine Hydrochloride)  
42879-47-0 (Pranolium Chloride)  
42924-53-8 (Nabumetone)  
42971-09-5 (Vinpocetine)  
43033-72-3 (Levomethadyl Acetate Hydrochloride)  
43143-11-9 (Bispyrithione Magsulfex)  
43200-80-2 (Zopiclone)  
43210-67-9 (Fenbendazole)  
47141-42-4 (Levobunolol)  
49562-28-9 (Fenofibrate)  
  
109636-76-2 (Prinomide Tromethamine)  
  
134523-03-8 (Atorvastatin Calcium)  
134564-82-2 (Befloxatone)  
134633-29-7 (Tecogalan sodium)  
134678-17-4 (Lamivudine)  
134861-62-4 (Dioxamycin)  
135038-56-1 (Glycopril)  
135038-57-2 (Fasidotril)  
135202-79-8 (Ilonidap)  
135247-46-0 (Tylogenin)  
135381-77-0 (Flezelastine)  
135383-02-7 (Stipiamide)  
REGISTRY NUMBER: 135459-90-4 (Ranelic acid)

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 12:54:17 ON 18 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21  
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Serial No.:10/582,410

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


=> D STAT QUE L50  
L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L26 2792 SEA FILE=REGISTRY SSS FUL L3


L35 STR



Structure attributes must be viewed using STN Express query preparation.

L37 321 SEA FILE=REGISTRY SUB=L26 SSS FUL L35

L38 STR



Structure attributes must be viewed using STN Express query preparation.

L39 1104 SEA FILE=REGISTRY SUB=L26 SSS FUL L38

L42 347 SEA FILE=HCAPLUS ABB=ON PLU=ON L37 AND L39

L43 250 SEA FILE=HCAPLUS ABB=ON PLU=ON L42 AND (PRY<=2005 OR  
AY<=2005 OR PY<=2005)

L46 152 SEA FILE=HCAPLUS ABB=ON PLU=ON L43 AND 63/SC, SX

L49 49418 SEA FILE=HCAPLUS ABB=ON PLU=ON DRUG DELIVERY SYSTEMS+NT/CT(L)  
(CAPSULE/OBI OR SACHET/OBI OR TABLET/OBI)

L50 60 SEA FILE=HCAPLUS ABB=ON PLU=ON L46 AND L49

=&gt; S L50 NOT L45,L52,L53

7024 L6  
 4045 L8  
 3789 L9  
 562 L10  
 1868 L12  
 13 L13  
 7024 L6  
 4045 L8  
 3789 L9  
 562 L10  
 1868 L12  
 13 L13

L55 56 L50 NOT (L45 OR L52 OR L53)

=&gt; D IBIB ED ABS HITSTR L55 1-56

L55 ANSWER 1 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1188473 HCAPLUS Full-text

DOCUMENT NUMBER: 149:432695

TITLE: Fenofibrate dosage forms

INVENTOR(S): Ryde, Tuula A.; Gustow, Evan E.; Ruddy, Stephen B.;  
Jain, Rajeev; Patel, Rakesh; Wilkins, Michael John;  
Ryde, Niels P.PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.; Fournier  
Laboratories Ireland, Ltd.SOURCE: U.S. Pat. Appl. Publ., 28pp., Cont.-in-part of U.S.  
Ser. No. 846,144, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 23

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080241070	A1	20081002	US 2008-58497	20080328 <--
US 6375986	B1	20020423	US 2000-666539	20000921 <--
US 20020110597	A1	20020815	US 2002-75443	20020215 <--
US 6592903	B2	20030715		
US 20040029099	A1	20040212	US 2002-323736	20021220 <--
US 7198795	B2	20070403		
US 20030224058	A1	20031204	US 2003-370277	20030221 <--
US 20050276974	A1	20051215	US 2003-444066	20030523 <--
US 7276249	B2	20071002		


PRIORITY APPLN. INFO.:	US 2000-666539	A1	20000921 <--
	US 2002-75443	A2	20020215 <--
	US 2002-383294P	P	20020524 <--
	US 2002-323736	A2	20021220 <--
	US 2003-370277	A2	20030221 <--
	US 2003-444066	A2	20030523 <--
	US 2005-303024	B2	20051216 <--
	US 2005-275278	B2	20051221 <--
	US 2006-433823	B1	20060515
	US 2007-650579	B1	20070108
	US 2007-846144	B2	20070828

ED Entered STN: 03 Oct 2008

AB Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also disclosed are in vitro methods for evaluating the in vivo effectiveness of fibrate, such as fenofibrate, dosage forms. The methods utilize media


representative of in vivo human physiol. conditions. Nanoparticulate fenofibrate formulations are prepared containing hypromellose and diocyl sodium succinate.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fenofibrate dosage forms)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 2 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:640693 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 149:1498  
 TITLE: Methods and compositions for controlling body weight and appetite  
 INVENTOR(S): Lipka, Arnold S.; Epstein, Joseph W.; Tizzano, Joseph T.; Basile, Anthony  
 PATENT ASSIGNEE(S): Dov Pharmaceutical, Inc., USA  
 SOURCE: PCT Int. Appl., '79 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008063673	A1	20080529	WO 2007-US24403	20071121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				

Serial No.:10/582,410

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM

US 20070225351 A1 20070927 US 2006-603974 20061121 <--  
US 20080234354 A1 20080925 US 2007-943552 20071120  
PRIORITY APPLN. INFO.: US 2006-603974 A 20061121  
US 2007-943552 A 20071120  
WO 2002-US845 W 20020111 <--  
US 2004-466457 A1 20040210 <--  
US 2006-442743 A2 20060530

ED Entered STN: 29 May 2008


AB The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The present invention provides novel compns. and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The methods and compns. of the invention may employ a (+)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(compns. for controlling body weight and appetite)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1309211 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:528186  
 TITLE: Nanoparticulate fibrate formulations  
 INVENTOR(S): Ryde, Tuula; Gustow, Evan E.; Jain, Rajeev; Patel, Rakesh; Wilkins, Michael John  
 PATENT ASSIGNEE(S): Elan Pharma International, Ltd., Ire.  
 SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 522,528.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 23  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070264348	A1	20071115	US 2007-710607	20070226 <--
US 20030224058	A1	20031204	US 2003-370277	20030221 <--
US 20050276974	A1	20051215	US 2003-444066	20030523 <--
US 7276249	B2	20071002		
PRIORITY APPLN. INFO.:			US 2002-383294P	P 20020524 <--
			US 2003-370277	A2 20030221 <--
			US 2003-444066	A2 20030523 <--
			US 2005-275278	B1 20051221 <--
			US 2006-522528	B2 20060918

ED Entered STN: 16 Nov 2007

AB The present invention is directed to fibrate compns. having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. Thus, formulation was prepared containing fenofibrate 5%, hydroxypropyl cellulose 1%, and dioctyl sodium sulfosuccinate 0.05%.


IT 49562-28-9, Fenofibrate

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nanoparticulate fibrate formulations)


RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (nanoparticulate fibrate formulations)  
 RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 4 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1088938 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:398709  
 TITLE: Methods and compositions for controlling body weight and appetite  
 INVENTOR(S): Lippa, Arnold S.; Epstein, Joseph W.; Basile, Anthony; Tizzano, Joseph T.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 27pp., Cont.-in-part of U.S. Ser. No. 442,743.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070225351	A1	20070927	US 2006-603974	20061121 <--
WO 2002066427	A2	20020829	WO 2002-US845	20020111 <--
WO 2002066427	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

Serial No.:10/582,410

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 20040132797 A1 20040708 US 2004-466457 20040210 <--  
 US 7098229 B2 20060829  
 US 20080234354 A1 20080925 US 2007-943552 20071120  
 WO 2008063673 A1 20080529 WO 2007-US24403 20071121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

WO 2002-US845 W 20020111 <--  
 US 2004-466457 A1 20040210 <--  
 US 2006-442743 A2 20060530  
 US 2001-758883 A 20010111 <--  
 US 2006-603974 A2 20061121  
 US 2007-943552 A 20071120

ED Entered STN: 28 Sep 2007

AB The present invention provides novel compns. and methods for the controlling  
 appetite and weight and/or treating obesity using a (+)-1-(3,4-  
 dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound The invention  
 also provides novel compns. and methods for treating or preventing disorders  
 related to or complicated by excessive body weight or obesity, including  
 coronary heart disease, osteoarthritis, osteoporosis, dyslipidemias, gout,  
 atherosclerosis, joint pain, sexual and fertility problems, respiratory  
 problems, gall bladder disease, skin conditions, hypertension, diabetes,  
 stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension,  
 lower extremity venous stasis disease, gastro-esophageal reflux, urinary  
 stress incontinence, metabolic syndrome, insulin resistance and cancer. The  
 methods and compns. of the invention may employ a (+)-1-(3,4-dichlorophenyl)-  
 3- azabicyclo[3.1.0]hexane or related compound alone, or in combination with a  
 second anti-appetite or anti-obesity agent.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(methods and compns. for controlling body weight and appetite)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:703828 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:102206  
 TITLE: Compressed solid dosage forms comprising drugs of low solubility and sugar and process for making the same  
 INVENTOR(S): Zalit, Ilan; Kopel, Mira  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.  
 SOURCE: PCT Int. Appl., 39pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007073389	A1	20070628	WO 2005-US47260	20051222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2626234 A1 20070628 CA 2005-2626234 20051222 <-- EP 1808163 A1 20070718 EP 2005-258010 20051222 <-- R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU IN 2008DN04349 A 20080815 IN 2008-DN4349 20080522 <-- PRIORITY APPLN. INFO.: WO 2005-US47260 W 20051222 <--				

ED Entered STN: 29 Jun 2007

AB One of the objects of the present invention is directed to a process of preparing a pharmaceutical formulation of a drug of low aqueous solubility, comprising (i) fixing the drug in a strong matrix comprising at least one at least partially amorphous sugar to obtain a sugar-drug matrix; and (ii)

milling the sugar-drug matrix to obtain a milled sugar-drug matrix as the pharmaceutical formulation. The invention also provides the pharmaceutical formulation prepared by the process. Thus, tablets containing 145 mg fenofibrate with improved drug dissoln. were prepared. An amorphous sugar was prepared by mixing 644 mg sucrose with 322  $\mu$ L water, heating the mixture to 125°, adding 128.8 mg glucose with continuous heating to 156°, cooling to room temperature and milling. The powder obtained was blended with fenofibrate 145 mg, sodium lauryl sulfate 50 mg, and PVP K30 100 mg and heated until the blend reached temperature of 60–80°, the mass was allowed to cool to room temperature, and then milled. Pregelatinized starch 217 mg, AcDiSol 50 mg, and Aerosil 200 13 mg were mixed, and then blended with the fenofibrate-containing powder, magnesium stearate 20 mg was added and the final blend was compressed into tablet.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation and milling of matrix containing sugar and drug of low aqueous solubility

for compressed solid dosage forms)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 6 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:647596 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:58382

TITLE: Pharmaceutical tablets with height greater than width

INVENTOR(S): Solomon, Lawrence; Kaplan, Allan S.

## Serial No.:10/582,410

PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S. Ser. No. 569,343.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070134321	A1	20070614	US 2006-561968	20061121 <--
AU 2005245026	A1	20051201	AU 2005-245026	20050523 <--
CA 2565029	A1	20051201	CA 2005-2565029	20050523 <--
WO 2005112897	A2	20051201	WO 2005-US18633	20050523 <--
WO 2005112897	A3	20060921		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1755564	A2	20070228	EP 2005-754425	20050523 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1964703	A	20070516	CN 2005-80016366	20050523 <--
JP 2008500402	T	20080110	JP 2007-527576	20050523 <--
IN 2006KN03323	A	20070615	IN 2006-KN3323	20061113 <--
US 20080003285	A1	20080103	US 2006-569343	20061117 <--
PRIORITY APPLN. INFO.:				
			US 2004-573042P	P 20040521 <--
			US 2004-573134P	P 20040521 <--
			WO 2005-US18633	W 20050523 <--
			US 2006-569343	A2 20061117

ED Entered STN: 15 Jun 2007

AB A compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet is described. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides. The layers can form a segment or, preferably, more than one segment. Thus, three segment, taller-than-wide tablets were prepared comprising (i) a bottom segment containing dibasic calcium phosphate 51.13, amlodipine besylate 7.15, Explotab 2.48, magnesium stearate 0.93, and FD&C Blue #1 Aluminum Lake 0.31, (ii) a middle segment containing Nu-Tab 194.00, and (iii) a top segment containing lactose monohydrate 42.03, benazepril HCl 9.00, Crospovidone 2.16, magnesium stearate 0.54, and FD&C Red #40 Aluminum Lake 0.27 mg, resp.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(taller-than-wide tablets with multiple layers and segments)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 7 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:644381 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:58365

TITLE: Therapeutic combinations comprising betaine and anti-cholesterol agent for reducing side effects on liver, pancreas and kidneys

INVENTOR(S): Messadek, Jallal

PATENT ASSIGNEE(S): Belg.

SOURCE: U.S. Pat. Appl. Publ., 16pp., Cont.-in-part of Appl. No. PCT/BE2006/000137.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070134324	A1	20070614	US 2007-625448	20070122 <--
BE 1016128	A6	20060307	BE 2004-364	20040722 <--
WO 2006007671	A2	20060126	WO 2005-BE112	20050713 <--
WO 2006007671	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

Serial No.:10/582,410

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

BE 2004-364

A 20040722 <--

WO 2005-BE112

A2 20050713 <--

WO 2006-BE137

A2 20061222

ED Entered STN: 15 Jun 2007

AB The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and oral co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys. Such therapeutic combinations allow to augment the compliance of the pharmaceutical dosage form while retaining and respecting correct conservation properties. Thus, fenofibrate co-micronized with glycine betaine was mixed to an aqueous solution containing 20 wt% glycine betaine. The mixture was maintained under agitation for 10 min before being lyophilized as to obtain a dry product containing 15 wt% of fenofibrate and 85 wt% of glycine betaine. The product was ground to a powder with granulometry size <5  $\mu$ m. Gelatin capsules were filled with 500 mg powder (75 mg of fenofibrate) and 750 powder mg (112.5 mg of fenofibrate).


IT 134523-03-8, Atorvastatin calcium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(betaine and anti-cholesterol agent therapeutic combinations for  
reducing side effects on liver, pancreas and kidneys)

RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

IT 49562-28-9, Fenofibrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(micronized, nanosized; betaine and anti-cholesterol agent therapeutic  
combinations for reducing side effects on liver, pancreas and kidneys)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



L55 ANSWER 8 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:620146 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:39188  
 TITLE: Composition comprising  
 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid  
 INVENTOR(S): Ju, Tzuchi R.; Engh, Kevin R.; Gao, Yi; Jayaraman,  
 Shyamala C.; Lee, Dennis Y.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 39pp., Cont.-in-part of U.S.  
 Ser. No. 400,113.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070128278	A1	20070607	US 2006-549005	20061012 <--
AU 2006258217	A1	20061221	AU 2006-258217	20060407 <--
CA 2604078	A1	20061221	CA 2006-2604078	20060407 <--
US 20070264334	A1	20071115	US 2006-400113	20060407 <--
EP 1868587	A2	20071226	EP 2006-799902	20060407 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008535851	T	20080904	JP 2008-505585	20060407 <--
MX 200712443	A	20071213	MX 2007-12443	20071005 <--
IN 2007DN07908	A	20071109	IN 2007-DN7908	20071012 <--
US 20080152714	A1	20080626	US 2007-871514	20071012 <--
NO 2007005628	A	20071105	NO 2007-5628	20071105 <--
KR 2008008352	A	20080123	KR 2007-726032	20071108 <--
CN 101217944	A	20080709	CN 2006-80020506	20071210 <--
PRIORITY APPLN. INFO.:				
			US 2005-669699P	P 20050408 <--
			US 2006-400113	A2 20060407
			US 2006-399964	A2 20060407
			US 2006-399983	A2 20060407
			WO 2006-US13121	W 20060407
			US 2006-548960	A2 20061012
			US 2006-548982	A2 20061012
			US 2006-549005	A2 20061012
			US 2006-829255P	P 20061012

ED Entered STN: 08 Jun 2007

AB The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. Thus, composition was containing 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic

Serial No.:10/582,410

acid 40%, dibasic calcium phosphate 15%, Avicel PH101 24%, PVP 30 5%, lactose monohydrate 15%, and magnesium stearate 1%.


IT 42017-89-0 42017-89-0D, salts 856676-23-8

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(composition comprising 2-[4-(4-chlorobenzoyl)phenoxy]-2-Me-propanoic acid)


RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)




RN 856676-23-8 HCAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate (1:1) (CA INDEX NAME)

CM 1

CRN 856676-22-7


CMF C17 H14 Cl O4



CM 2


CRN 62-49-7

CMF C5 H14 N O



IT 134523-00-5, Atorvastatin  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (composition comprising 2-[4-(4-chlorobenzoyl)phenoxy]-2-Me-propanoic acid)  
 RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-  
 (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-  
 (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 9 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:461081 HCAPLUS Full-text  
 DOCUMENT NUMBER: 146:415079  
 TITLE: Methods and compositions for treatment of prostate  
 intraepithelial neoplasia  
 INVENTOR(S): Zweig, Jack I.  
 PATENT ASSIGNEE(S): Zweig, Jack, I., USA  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007047553	A2	20070426	WO 2006-US40307	20061012 <--
WO 2007047553	A3	20080103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-726753P P 20051014 <--  
 ED Entered STN: 27 Apr 2007


Serial No.:10/582,410

AB Provided herein are methods of treatment of prostate intraepithelial neoplasia (PIN) by administering bexarotene. Also provided are pharmaceutical compns. and dosing regimens.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and compns. for treatment of prostate intraepithelial neoplasia with bexarotene)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 10 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:63345 HCAPLUS Full-text

DOCUMENT NUMBER: 146:149041

TITLE: Granulation process for poorly water-soluble drugs

INVENTOR(S): Zalit, Ilan; Hrakovsky, Julia; Tenengauzer, Ruth; Shalom-Klein, Sagit

PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 10pp.  
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070014854	A1	20070118	US 2005-181822	20050715 <--
CA 2614468	A1	20070125	CA 2005-2614468	20050715 <--

Serial No.:10/582,410

WO 2007011349 A1 20070125 WO 2005-US25326 20050715 <--  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
EP 1793801 A1 20070613 EP 2005-772375 20050715 <--  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU  
IN 2008DN00089 A 20080627 IN 2008-DN89 20080103 <--  
CN 101222911 A 20080716 CN 2005-80051050 20080111 <--  
PRIORITY APPLN. INFO.: US 2005-181822 A 20050715 <--  
WO 2005-US25326 W 20050715 <--

ED Entered STN: 19 Jan 2007


AB One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one sugar, and optionally 1 excipient other than the sugar, wherein the API has a water solubility of <20 mg/mL. The excipient other than the sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosylpyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising 1 sugar, e.g., a pyranosylpyranose such as lactose, and a solvent, and optionally 1 excipient other than the sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b). Thus, a formulation contained bicalutamide 50.0, Avicel PH102 20.0, Aerosil-200 3.0, lactose monohydrate 30.8, Povidone 3.0, sodium starch glycolate 20.0, and Mg stearate 1.2 parts.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(granulation process for poorly water-soluble drugs)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 11 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:63188 HCAPLUS Full-text  
 DOCUMENT NUMBER: 146:149037  
 TITLE: Pharmaceutical granulate comprising pyranosyl pyranose  
 INVENTOR(S): Zalit, Ilan; Hrakovsky, Julia; Tenengauzer, Ruth;  
 Shalom-Klein, Sagit  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries, Ltd., Israel  
 SOURCE: U.S. Pat. Appl. Publ., 10pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070014864	A1	20070118	US 2005-181820	20050715 <--
PRIORITY APPLN. INFO.:			US 2005-181820	20050715 <--

ED Entered STN: 19 Jan 2007

AB One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/mL. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate. For example, tablet was prepared containing bicalutamide 50, Avicel PH 102 20, Aerosil 200 3, lactose monohydrate 30.8, PVP k-3- 3, sodium starch glycolate 20 and magnesium stearate 1.2.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

Serial No.:10/582,410

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical granulate comprising pyranosyl pyranose)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 12 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:62910 HCAPLUS Full-text

DOCUMENT NUMBER: 146:149036

TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin

INVENTOR(S): Holm, Per; Norling, Tomas

PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.

SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of PCT/DK2005/050001.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070014846	A1	20070118	US 2006-456566	20060711 <--
WO 2005034908	A2	20050421	WO 2004-DK668	20041001 <--
WO 2005034908	A3	20050811		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

Serial No.:10/582,410

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

US 20070009603 A1 20070111 US 2004-988917 20041115 <--  
 WO 2006037344 A1 20060413 WO 2005-DK50001 20051003 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
 YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

WO 2006037347 A1 20060413 WO 2005-DK50004 20051003 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
 YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

US 20070190138 A1 20070816 US 2007-673270 20070209

PRIORITY APPLN. INFO.:

DK 2003-1503 A 20031010 <--  
 DK 2004-464 A 20040323 <--  
 DK 2004-1506 A 20041001 <--  
 WO 2004-DK668 A2 20041001 <--  
 DK 2004-1761 A 20041115 <--  
 US 2004-988917 A2 20041115 <--  
 DK 2005-196 A 20050209 <--  
 DK 2005-534 A 20050413 <--  
 WO 2005-DK50001 A2 20051003 <--  
 WO 2005-DK50004 A2 20051003 <--  
 US 2006-790449P P 20060407  
 DK 2004- A 20041223 <--  
 DK 2006-203 A 20060210

ED Entered STN: 19 Jan 2007

AB Pharmaceutical compns. in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG-CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compns. are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled-release or a delayed-release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

IT 49562-23-9, Fenofibrate 134523-00-5, Atorvastatin

Serial No.:10/582,410


134523-03-8, Atorvastatin calcium 344423-98-9

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 344423-98-9 HCAPLUS

Serial No.:10/582,410

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, hydrate (2:1:3), ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

● 3/2 H<sub>2</sub>O

L55 ANSWER 13 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:41338 HCAPLUS Full-text  
 DOCUMENT NUMBER: 146:128665  
 TITLE: Compositions comprising fenofibrate and atorvastatin  
 INVENTOR(S): Holm, Per; Norling, Tomas  
 PATENT ASSIGNEE(S): Den.  
 SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of Appl. No. PCT/DK04/000668.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070009603	A1	20070111	US 2004-988917	20041115 <--
WO 2005034908	A2	20050421	WO 2004-DK668	20041001 <--
WO 2005034908	A3	20050811		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20070026062	A1	20070201	US 2006-449918	20060609 <--
US 20070014846	A1	20070118	US 2006-456566	20060711 <--
PRIORITY APPLN. INFO.:			DK 2003-1503	A 20031010 <--
			DK 2004-464	A 20040323 <--

WO 2004-DK668	A2 20041001 <--
DK 2004-1506	A 20041001 <--
DK 2004-1761	A 20041115 <--
US 2004-988917	A2 20041115 <--
DK 2005-196	A 20050209 <--
DK 2005-527	A 20050413 <--
DK 2005-534	A 20050413 <--
WO 2005-DK50001	A2 20051003 <--
WO 2005-DK50004	A2 20051003 <--
US 2006-787472P	P 20060329
US 2006-790449P	P 20060407

ED Entered STN: 12 Jan 2007


AB The present invention relates to pharmaceutical compns. in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC<sub>0-24</sub> value (AUC<sub>fenofibrate</sub>/AUC<sub>atorvastatin</sub>) of between about 250 and about 10,000. The solid compns. are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and atorvastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability. Thus, immediate release tablet was prepared containing fenofibrate 23.9%, atorvastatin 1.5%, lactose 37.6%, PEG 25.6%, Poloxamer 188 11%, and magnesium stearate 0.4%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS


CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 344920-08-7  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compsns. comprising fenofibrate and atorvastatin)  
 RN 344920-08-7 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, hydrate  
 (2:1:6), ( $\beta,\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

● 3 H<sub>2</sub>O

L55 ANSWER 14 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:343940 HCAPLUS Full-text  
 DOCUMENT NUMBER: 144:376530  
 TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin  
 INVENTOR(S): Holm, Per; Norling, Tomas  
 PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006037344	A1	20060413	WO 2005-DK50001	20051003 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2582403	A1	20060413	CA 2005-2582403	20051003 <--

Serial No.:10/582,410

EP 1804769	A1	20070711	EP 2005-789004	20051003 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20070026062	A1	20070201	US 2006-449918	20060609 <--
US 20070014846	A1	20070118	US 2006-456566	20060711 <--
IN 2007CN01883	A	20070831	IN 2007-CN1883	20070503 <--
PRIORITY APPLN. INFO.:			DK 2004-1506	A 20041001 <--
			DK 2004-1761	A 20041115 <--
			DK 2004-	A 20041223 <--
			DK 2005-196	A 20050209 <--
			DK 2005-534	A 20050413 <--
			DK 2003-1503	A 20031010 <--
			DK 2004-464	A 20040323 <--
			WO 2004-DK668	A2 20041001 <--
			US 2004-988917	A2 20041115 <--
			DK 2005-527	A 20050413 <--
			WO 2005-DK50001	W 20051003 <--
			WO 2005-DK50004	A2 20051003 <--
			US 2006-787472P	P 20060329
			US 2006-790449P	P 20060407

ED Entered STN: 14 Apr 2006


AB Pharmaceutical compns. are disclosed in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC<sub>0-24</sub> value (AUC<sub>fenofibrate</sub>/AUC<sub>atorvastatin</sub>) of between about 250 and about 10,000. The solid compns. are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 15 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:343414 HCAPLUS Full-text  
 DOCUMENT NUMBER: 144:376521  
 TITLE: Pharmaceutical compositions comprising fenofibrate and atorvastatin  
 INVENTOR(S): Holm, Per; Norling, Tomas  
 PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006037347	A1	20060413	WO 2005-DK50004	20051003 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2582405	A1	20060413	CA 2005-2582405	20051003 <--
EP 1804768	A1	20070711	EP 2005-789000	20051003 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20070026062	A1	20070201	US 2006-449918	20060609 <--
US 20070014846	A1	20070118	US 2006-456566	20060711 <--
IN 2007CN01880	A	20070831	IN 2007-CN1880	20070503 <--
PRIORITY APPLN. INFO.:				
			DK 2004-1506	A 20041001 <--
			DK 2004-1761	A 20041115 <--
			DK 2004-	A 20041223 <--
			DK 2005-196	A 20050209 <--
			DK 2005-534	A 20050413 <--
			DK 2003-1503	A 20031010 <--
			DK 2004-464	A 20040323 <--
			WO 2004-DK668	A2 20041001 <--

Serial No.:10/582,410

US 2004-988917	A2 20041115 <--
DK 2005-527	A 20050413 <--
WO 2005-DK50001	A2 20051003 <--
WO 2005-DK50004	W 20051003 <--
US 2006-787472P	P 20060329
US 2006-790449P	P 20060407

ED Entered STN: 14 Apr 2006

AB Pharmaceutical compns. are disclosed in particulate form or in solid dosage forms comprising a combination of a reduced or low dose of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof. Atorvastatin is optionally provided as a controlled release or a delayed release formulation, which may result in a maintained LDL-lowering effect at a reduced dosage. Fenofibrate is provided in a formulation being bioequivalent to com. available Antara capsules, or exhibiting increased bioavailability as compared thereto, and also reduced food effect.


IT 49562-28-9, Antara 134523-00-5, Atorvastatin

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(pharmaceutical compns. comprising fenofibrate and atorvastatin)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 16 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:76446 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:156741

TITLE: Therapeutic combinations containing a betaine and an

## Serial No.:10/582,410

anticholesterol agent  
 INVENTOR(S): Messadek, Jallal  
 PATENT ASSIGNEE(S): Belg.  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006007671	A2	20060126	WO 2005-BE112	20050713 <--
WO 2006007671	A3	20060223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
BE 1016128	A6	20060307	BE 2004-364	20040722 <--
EP 1773450	A2	20070418	EP 2005-763958	20050713 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070134324	A1	20070614	US 2007-625448	20070122 <--
PRIORITY APPLN. INFO.:				
			BE 2004-364	A 20040722 <--
			WO 2005-BE112	W 20050713 <--
			WO 2006-BE137	A2 20061222

ED Entered STN: 27 Jan 2006


AB The invention relates to a pharmaceutical composition containing a betaine and an anti-cholesterol agent. The association and co-administration of at least one type of betaine makes it possible to reduce secondary effects accompanying the administration of anticholesterol agents, in particular harmful effects on the liver, pancreas and kidney. A tablet contained anhydrous betaine 350.00, micronized fenofibrate (5-20 µm) 60.00, lactose 35.00, Et cellulose 90.00, cetostearyl alc. 32.00, magnesium stearate 17.00, and talc 16.00 mg.

IT 49562-28-9, Fenofibrate 134523-03-8, Atorvastatin calcium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (therapeutic combinations containing betaine and anticholesterol agent)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-03-8 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

L55 ANSWER 17 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:7329 HCAPLUS Full-text

DOCUMENT NUMBER: 144:94360

TITLE: Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols

INVENTOR(S): Udell, Ronald G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 145,563.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060003947	A1	20060105	US 2005-176593	20050707 <--
US 20050249803	A1	20051110	US 2005-145563	20050603 <--
WO 2006132879	A2	20061214	WO 2006-US21079	20060530 <--
WO 2006132879	A3	20070823		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-145563 A2 20050603 <--  
US 2005-176593 A 20050707 <--


ED Entered STN: 05 Jan 2006

AB The present invention is directed to soft gel compns., methods of delivery and packaged nutraceuticals of the soft gel compns. that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Optional active ingredients include a phytosterol, DHA, EPA, coenzyme Q-10 or an analog thereof and mixts. thereof.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 18 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1201058 HCAPLUS Full-text

DOCUMENT NUMBER: 143:446808

TITLE: Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols

INVENTOR(S): Udell, Ronald G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 18 pp.  
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 20050249803	A1	20051110	US 2005-145563	20050603 <--
US 20060003947	A1	20060105	US 2005-176593	20050707 <--
WO 2006132879	A2	20061214	WO 2006-US21079	20060530 <--
WO 2006132879	A3	20070823		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2005-145563	A2 20050603 <--
US 2005-176593	A 20050707 <--

ED Entered STN: 11 Nov 2005

AB The present invention is directed to soft gel compns., methods of delivery and packaged nutraceuticals of the soft gel compns. that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Serum samples obtained from healthy subjects following oral administration of 2 different Sytrinol formulations contained detectable amts. of tangeretin and nobiletin.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 19 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1004560 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:292574  
 TITLE: Co-formulations of kits of bioactive agents  
 INVENTOR(S): Borsadia, Suresh  
 PATENT ASSIGNEE(S): Abeille Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084666	A1	20050915	WO 2005-US6043	20050228 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1734953	A1	20061227	EP 2005-714070	20050228 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2007526309	T	20070913	JP 2007-501850	20050228 <--
US 20070098778	A1	20070503	US 2006-595884	20060518 <--
PRIORITY APPLN. INFO.:			US 2004-549420P	P 20040302 <--
			WO 2005-US6043	W 20050228 <--

ED Entered STN: 16 Sep 2005

AB A formulation or kit is provided comprising: (a) 1 or more glucose-level-controlling bioactive agents selected from an  $\alpha$ -glucosidase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPAR  $\alpha/\gamma$  agonist, PPAR  $\alpha/\gamma$  agonist or insulin secretagogue; and (b) an antihypertensive selected from an ACE inhibitor, calcium channel blocker,  $\beta$ -blocker, angiotensin II receptor antagonist or diuretic, or one or more of an anti-dyslipidemia agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative. In the case of a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group


(a) that is a thiazolidinedione or dual PPAR  $\alpha/\gamma$  agonist with an angiotensin II receptor antagonist, one or more of the following applies: one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or the co-formulation or kit comprises a biguanide and a thiazolidinedione and one or more group (b) bioactive agents. Thus, a formulation contained metformin-HCl 66.7, microcryst. cellulose 16.7, and Eudragit NE40D 16.7%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (co-formulations of kits of bioactive agents)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 20 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1001853 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 143:311933  
 TITLE: Compositions of bioactive compounds from Fenugreek seed and methods for producing same  
 INVENTOR(S): Lee, Steve S.; Hynson, Richard B.; Zhang, Ke-Qin; Li, Wu-Zhou; Zhou, Jing Shi  
 PATENT ASSIGNEE(S): Technical Sourcing International, Inc., USA  
 SOURCE: PCT Int. Appl., 71 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084323	A2	20050915	WO 2005-US6676	20050302 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050233013	A1	20051020	US 2005-68734	20050301 <--
US 20050233014	A1	20051020	US 2005-69836	20050301 <--
US 20050238738	A1	20051027	US 2005-69747	20050301 <--
PRIORITY APPLN. INFO.:			US 2004-549198P	P 20040302 <--
			US 2005-68734	A 20050301 <--
			US 2004-549305P	P 20040302 <--

ED Entered STN: 15 Sep 2005

AB The present invention is directed to novel compns. of bioactive compds. comprising 4-hydroxyisoleucine and one or more compds. selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compns. of bioactive compds. include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, and gamma-aminobutyrate. The composition of bioactive compds. preferably include about 10 to 70% of 4-hydroxyisoleucine and about 20 to 40% of other amino acids. The bioactive compds. of the novel composition of the present invention may be derived, isolated, and/or extracted from Fenugreek seeds. A preferred method for extracting the bioactive compds. from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bioactive compds. from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compns. of bioactive compds. have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination with; preparation of compns. of bioactive compds. from Fenugreek seed affecting homeostasis and metabolism)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 21 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:823553 HCAPLUS Full-text

DOCUMENT NUMBER: 143:199940

TITLE: Combination drug containing antihyperlipidemics and  $\alpha$ -glucosidase inhibitors

INVENTOR(S): Kanazawa, Hashime; Ishitani, Kouki; Sudo, Katsuichi; Tanimori, Naoto

PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074909	A1	20050818	WO 2005-JP1801	20050208 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2555316	A1	20050818	CA 2005-2555316	20050208 <--
EP 1714648	A1	20061025	EP 2005-709853	20050208 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
US 20070197602	A1	20070823	US 2006-588725	20060808 <--
PRIORITY APPLN. INFO.:			JP 2004-32329	A 20040209 <--
			WO 2005-JP1801	W 20050208 <--

ED Entered STN: 19 Aug 2005

AB Disclosed is a drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compds. (fenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase inhibitors (statin compds. such as pravastatin, atorvastatin, salts thereof, etc.) with an  $\alpha$ -glucosidase inhibitor (voglibose, acarbose, etc.). The content of the  $\alpha$ -glucosidase inhibitor may be from 0.001 to 50 parts by weight per 100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to provide a drug having excellent effects of preventing and/or treating metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc. with little side effect. For example, the effect of combination of fenofibrate and voglibose was examined in streptozotocin-induced diabetic rats. Also, a tablet containing fenofibrate 100, voglibose 0.2, lactose 69.2, fine crystalline cellulose 29.6, magnesium stearate 1 mg was formulated.

IT 861998-84-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination drug containing antihyperlipidemics and  $\alpha$ -glucosidase inhibitors)

RN 861998-84-7 HCAPLUS


CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-, mixt. with 1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate (9CI) (CA INDEX NAME)

CM 1

CRN 83480-29-9

CMF C10 H21 N O7


Absolute stereochemistry. Rotation (+).




CM 2

CRN 49562-28-9


CMF C20 H21 Cl O4



IT 42017-89-0, Fenofibric acid 49562-28-9, Fenofibrate  
 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination drug containing antihyperlipidemics and  $\alpha$ -glucosidase  
 inhibitors)  
 RN 42017-89-0 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)




RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(  
 (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 22 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:523236 HCAPLUS [Full-text](#)

## Serial No.:10/582,410

DOCUMENT NUMBER: 143:48119  
 TITLE: Reverse micelle formulations comprising one or more surfactant, a hydrophilic phase and lipophilic or hydrophobic compounds  
 INVENTOR(S): Liang, Likan  
 PATENT ASSIGNEE(S): Shire Laboratories, Inc., USA  
 SOURCE: PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053612	A2	20050616	WO 2004-US39567	20041124 <--
WO 2005053612	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2537029	A1	20050616	CA 2004-2537029	20041124 <--
US 20050191343	A1	20050901	US 2004-995942	20041124 <--
EP 1706098	A2	20061004	EP 2004-812147	20041124 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007512373	T	20070517	JP 2006-541711	20041124 <--
PRIORITY APPLN. INFO.:				
			US 2003-525572P	P 20031126 <--
			US 2004-541389P	P 20040202 <--
			US 2004-566157P	P 20040428 <--
			WO 2004-US39567	W 20041124 <--
ED	Entered STN: 17 Jun 2005			
AB	The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compds., particularly therapeutic compds. The formulations contains one or more non-ionic surfactants or a mixture of nonionic and ionic surfactants, a hydrophilic phase composed of one or more hydrophilic solvents and/or solubilizers and/ or aqueous media, and one or more therapeutically active, hydrophobic agents. The compns. optionally further contain P-glycoprotein inhibitors, absorption enhancers or promoters, tight junction modulators, lipid membrane mobilizers, and antioxidants. For example, fenofibrate reverse micelle systems containing both hydrophilic and surfactant-miscible solubilizers were prepared containing PEG-8-caprylic/capric glycerides 6 g, PEG-4 lauryl ether 3.7 g, PEG 400 0.15 g, water 0.15 g and fenofibrate 1 g.			
IT	49562-28-9, Fenofibrate 134523-00-5, Atorvastatin			
	RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(reverse micelle formulations comprising surfactants, hydrophilic phase, and lipophilic or hydrophobic compds.)			
RN	49562-28-9 HCAPLUS			
CN	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)			



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 23 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:346827 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 142:397743  
 TITLE: A solid dosage form comprising a fibrate and a statin  
 INVENTOR(S): Holm, Per; Norling, Tomas  
 PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034908	A2	20050421	WO 2004-DK668	20041001 <--
WO 2005034908	A3	20050811		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004279661	A1	20050421	AU 2004-279661	20041001 <--
CA 2541382	A1	20050421	CA 2004-2541382	20041001 <--

Serial No.:10/582,410

EP 1680086 A2 20060719 EP 2004-762888 20041001 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 BR 2004015121 A 20061128 BR 2004-15121 20041001 <--  
 CN 1874758 A 20061206 CN 2004-80031841 20041001 <--  
 JP 2007508249 T 20070405 JP 2006-529649 20041001 <--  
 US 20050096390 A1 20050505 US 2004-988818 20041115 <--  
 US 20050096391 A1 20050505 US 2004-988829 20041115 <--  
 US 20060105050 A1 20060518 US 2004-988828 20041115 <--  
 US 20070009603 A1 20070111 US 2004-988917 20041115 <--  
 US 20060068015 A1 20060330 US 2005-513778 20050714 <--  
 MX 2006PA03813 A 20060614 MX 2006-PA3813 20060405 <--  
 IN 2006CN01583 A 20070608 IN 2006-CN1583 20060509 <--  
 US 20070026062 A1 20070201 US 2006-449918 20060609 <--  
 US 20070014846 A1 20070118 US 2006-456566 20060711 <--  
 PRIORITY APPLN. INFO.: DK 2003-1503 A 20031010 <--  
 DK 2004-464 A 20040323 <--  
 DK 2004-1506 A 20041001 <--  
 WO 2004-DK668 W 20041001 <--  
 DK 2004-1761 A 20041115 <--  
 US 2004-988917 A2 20041115 <--  
 DK 2005-196 A 20050209 <--  
 DK 2005-527 A 20050413 <--  
 DK 2005-534 A 20050413 <--  
 WO 2005-DK50001 A2 20051003 <--  
 WO 2005-DK50004 A2 20051003 <--  
 US 2006-787472P P 20060329  
 US 2006-790449P P 20060407

ED Entered STN: 22 Apr 2005

AB The present invention relates to pharmaceutical compns. in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors). The compns. are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e., the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration. Thus, tablets contained fenofibrate 160.09, PEG 208.12, Poloxamer-188 89.19, lactose 356.51, and Mg stearate 4.09 mg.


IT 49562-28-9, Fenofibrate

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid dosage form comprising fibrate and statin)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




IT 42017-89-0, Fenofibric acid 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solid dosage form comprising fibrate and statin)

RN 42017-89-0 HCAPLUS

Serial No.:10/582,410


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 24 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:220154 HCAPLUS Full-text

DOCUMENT NUMBER: 142:285226

TITLE: Multi-system therapy for diabetes, the metabolic syndrome and obesity

INVENTOR(S): Folli, Franco; Manfredi, Paolo; Gonzales, Gilbert

PATENT ASSIGNEE(S): Italy

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050054731	A1	20050310	US 2004-868227	20040615 <--
CA 2538333	A1	20050324	CA 2004-2538333	20040826 <--
WO 2005025673	A1	20050324	WO 2004-US27689	20040826 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

Serial No.:10/582,410

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

EP 1663395 A1 20060607 EP 2004-782221 20040826 <--  
R: DE, ES, FR, GB, IT  
IN 2006DN01141 A 20070810 IN 2006-DN1141 20060303 <--  
PRIORITY APPLN. INFO.: US 2003-501226P P 20030908 <--  
US 2004-868227 A 20040615 <--  
WO 2004-US27689 W 20040826 <--


ED Entered STN: 13 Mar 2005

AB A multi-system therapy which is adapted to treat diabetes, metabolic syndrome and obesity includes a hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent. The composition can further include various vitamins and supplements such as vitamin B6, vitamin B12, arginine, a folate and other vitamins and minerals. Preferably, the hypoglycemic agent is a biguanide hypoglycemic agent without any addnl. hypoglycemic agent, making the composition suitable for treatment of individuals who are not hyperglycemic as well as those who are hyperglycemic. A capsule contained metformin 250, aspirin 12.5, simvastatin 3.5, lisinopril 1.66, folic acid 0.166, vitamin B6 8.33, and vitamin B12 0.166 mg. Efficacy of the composition was studied in mice.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(multi-system therapy for diabetes, metabolic syndrome and obesity)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ ) - (CA INDEX NAME)

Absolute stereochemistry.



## Serial No.:10/582,410

DOCUMENT NUMBER: 142:266843  
 TITLE: Osmotic delivery of drugs by solubility enhancement  
 INVENTOR(S): Kidane, Argaw; Ray, Shimul K.; Bhatt, Padmanabh P.;  
 Bryan, Jones W.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 22 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050053653	A1	20050310	US 2003-655725	20030905 <--
CA 2535060	A1	20050317	CA 2004-2535060	20040907 <--
WO 2005023228	A1	20050317	WO 2004-US28875	20040907 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1660051	A1	20060531	EP 2004-783203	20040907 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007504270	T	20070301	JP 2006-526205	20040907 <--
PRIORITY APPLN. INFO.:			US 2003-655725	A 20030905 <--
			WO 2004-US28875	W 20040907 <--


ED Entered STN: 11 Mar 2005

AB The present invention is directed to the oral osmotic delivery of drugs that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load. Thus, a formulation contained 2.24, Xylitol CM90 44.45, Maltrin M150 (wet) 1.31, Maltrin M150 (dry) 45.09, meglumine 4.94, Mg stearate 0.98, and stearic acid 0.98%.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (osmotic delivery of drugs by solubility enhancement)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 26 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:965034 HCAPLUS Full-text  
 DOCUMENT NUMBER: 141:400958  
 TITLE: Drug formulations with methacrylic acid-methylacrylate-ethylacrylate-butylmethacrylate copolymer containing coating or matrix  
 INVENTOR(S): Petereit, Hans-Ulrich; Meier, Christian; Schultes, Klaus  
 PATENT ASSIGNEE(S): Roehm G.m.b.H. & Co. K.-G., Germany  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096185	A1	20041111	WO 2004-EP2061	20040302 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10319458	A1	20041118	DE 2003-10319458	20030429 <--
CA 2489064	A1	20041111	CA 2004-2489064	20040302 <--
EP 1496870	A1	20050119	EP 2004-716230	20040302 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004003949	A	20050301	BR 2004-3949	20040302 <--
CN 1697649	A	20051116	CN 2004-80000276	20040302 <--
JP 2006524643	T	20061102	JP 2006-504498	20040302 <--
IN 2004CN02444	A	20070907	IN 2004-CN2444	20040827 <--

Serial No.:10/582,410

US 20050152977 A1 20050714 US 2004-512860 20041115 <--  
 PRIORITY APPLN. INFO.: DE 2003-10319458 A 20030429 <--  
 WO 2004-EP2061 W 20040302 <--


ED Entered STN: 12 Nov 2004

AB The invention relates to a method for producing a coated dosage form or a dosage form in the form of a matrix containing an active substance. The dosage form is produced by processing a copolymer that contains a pharmaceutical active substance, an optional core and/or pharmaceutically conventional aggregates in a manner known per se by melting, injection-molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compaction to give a coated dosage form and/or to give a matrix containing an active substance. The method is characterized in that a copolymer is used that is composed of 20 to 33 % by weight of methacrylic acid, 5 to 30 % by weight of Me acrylate, 20 to 40 % by weight of Et acrylate, and more than 10 to 30 % by weight of Bu methacrylate and optionally 0 to 10 % by weight of addnl. vinylically copolymerizable monomers, with the proviso that the glass temperature of the copolymer is 55 to 70° according to ISO 11357-2, item 3.3.3. The invention also relates to the dosage form produced according to the invention, to the copolymer and to the use thereof. Thus a copolymer composed of (weight/weight%): methacrylic acid 30; methylacrylate 20; ethylacrylate 30 and butylmethacrylate 20 was used for the coating of quinidine sulfate; 469.7 g of the emulsion copolymerizate was mixed with 8.5 g polysorbate 80 (33% aqueous solution), 7.0 g glycerol monostearate and 268.7 g water. The coating suspension was applied in a spray-coating apparatus onto 200 g quinidine sulfate cores to result a 6.0 mg/cm<sup>2</sup> coating.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (drug formulations with methacrylic  
 acid-methylacrylate-ethylacrylate-butylmethacrylate copolymer containing  
 coating or matrix)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-  
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 27 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:631261 HCAPLUS Full-text  
 DOCUMENT NUMBER: 141:162365  
 TITLE: Oral drug delivery systems with immediate dissolution and release that mask the unpleasant taste of the active substance and method for their preparation  
 INVENTOR(S): Petereit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas  
 PATENT ASSIGNEE(S): Roehm GmbH & Co. KG, Germany  
 SOURCE: Ger. Offen., 9 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10304403	A1	20040805	DE 2003-10304403	20030128 <--
CA 2512738	A1	20040812	CA 2003-2512738	20031121 <--
WO 2004066976	A1	20040812	WO 2003-EP13059	20031121 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003292061	A1	20040823	AU 2003-292061	20031121 <--
EP 1587497	A1	20051026	EP 2003-767591	20031121 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003018049	A	20051220	BR 2003-18049	20031121 <--
JP 2006514660	T	20060511	JP 2004-567296	20031121 <--
US 20060051412	A1	20060309	US 2005-542283	20050715 <--
MX 2005PA07643	A	20050930	MX 2005-PA7643	20050718 <--
IN 2005CN01698	A	20070622	IN 2005-CN1698	20050726 <--
PRIORITY APPLN. INFO.:			DE 2003-10304403	A 20030128 <--
			WO 2003-EP13059	W 20031121 <--

ED Entered STN: 06 Aug 2004

AB The invention concerns oral drug delivery systems with immediate dissoln. and release that mask the unpleasant taste of the active substance and that are prepared by intense mixing of (a) an anionic drug; (b) a copolymer of acrylic acid or methacrylic acid C1-C4 esters with (meth)acrylate monomers containing tertiary amino-groups; (c) 5-50 weight/weight% rel. to (b) C12-C22 carboxylic acid; the mixture is melted, mixed, kneaded, cooled and ground to 200 µm size powder particles. The powder is embedded into a water-soluble matrix with other pharmaceutical auxiliary components in a way that the amount of emulsifiers with HLB ≥ 14 does not exceed 3 weight/weight% in relation to the copolymer. Mixing is performed in twin-screw extruders at 80-200 °C; pressing, casting, granulation or freeze drying is used for embedding. Thus a

Serial No.:10/582,410

composition was prepared from (g): Eudragit E PO 39.42; stearic acid 35.2; ibuprofen 16.9; talc 8.4. The mixture was kneaded at 100°C for 20 min; 1 g of the cooled composition was tasted; after 2 min no bitterness was sensed.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral drug delivery systems with immediate dissoln. and release to mask taste of active substance and method for their preparation)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 28 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:533962 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:82335

TITLE: Human glucagon-like-peptide-1 mimics and their antidiabetic effects

INVENTOR(S): Natarajan, Sesha Iyer; Mapelli, Claudio; Bastos, Margarita M.; Bernatowicz, Michael; Lee, Ving; Ewing, William R.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U.S. Ser. No. 273,975.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

Serial No.:10/582,410

US 20040127423	A1	20040701	US 2003-419399	20030421 <--
US 7238671	B2	20070703		
US 20030195157	A1	20031016	US 2002-273975	20021018 <--
US 7238670	B2	20070703		
WO 2004094461	A2	20041104	WO 2004-US12374	20040421 <--
WO 2004094461	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1615653	A2	20060118	EP 2004-760098	20040421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070287670	A1	20071213	US 2007-740031	20070425 <--

PRIORITY APPLN. INFO.:

US 2001-342015P	P	20011018 <--
US 2002-273975	A2	20021018 <--
US 2003-419399	A	20030421 <--
WO 2004-US12374	W	20040421 <--

ED Entered STN: 02 Jul 2004

AB The invention discloses human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the invention provides novel, chemical modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulintropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(human glucagon-like-peptide-1 mimics and their antidiabetic effects)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 122 THERE ARE 122 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L55 ANSWER 29 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:490278 HCAPLUS Full-text  
DOCUMENT NUMBER: 141:42922  
TITLE: Hydrophobic active agent compositions and methods  
INVENTOR(S): Chen, Feng-Jing; Gutke, Kathryn; Venkateshwaran,  
Srinivasan; Patel, Mahesh V.  
PATENT ASSIGNEE(S): Lipocine, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 27 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040115287	A1	20040617	US 2002-322344	20021217 <--
PRIORITY APPLN. INFO.:			US 2002-322344	20021217 <--
ED Entered STN: 17 Jun 2004				
AB Compns. and methods for providing hydrophobic active agents in a bioavailable form, including cyclosporine are disclosed. In one aspect of the invention, a cyclosporine composition may be formulated that produces an aqueous dispersion containing cyclosporine in both dissolved and undissolved forms. In another aspect, the undissolved form of cyclosporine may be indicated by retention of cyclosporine particles on a 0.2 µm membrane upon filtration of the aqueous dispersion therewith. In another aspect, the undissolved form of cyclosporine may be indicated by formation of a pellet upon centrifugation of the aqueous dispersion at about 12 K+G for about 10 min. A claimed pharmaceutical composition comprises: a therapeutically effective amount of cyclosporine; a solubilizer of ethanol; and a stabilizer of a polyethoxylated castor oil and a polyethoxylated hydrogenated castor oil, in an amount sufficient to provide a ratio of stabilizer to cyclosporine of at least about 5:1, wherein upon contact with an aqueous medium, the composition forms a bioavailable dispersion of dissolved cyclosporine and particles containing undissolved cyclosporine, with at least about 35 % of the cyclosporine being dissolved.				
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical dispersions containing hydrophobic drug and solubilizer and stabilizer)				
RN 49562-28-9 HCAPLUS				
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)				



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 30 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:490267 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:42919

TITLE: Free-flowing solid formulations with improved  
bio-availability of poorly water soluble drugs and  
process for making the same

INVENTOR(S): Li, Wenji; Alosio, Edward; Dema-Ala, Bricini Faith;  
Nguyen, Amy

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040115226	A1	20040617	US 2002-317657	20021212 <--
WO 2004054540	A2	20040701	WO 2003-US38979	20031209 <--
WO 2004054540	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

Serial No.:10/582,410

AU 2003300833	A1	20040709	AU 2003-300833	20031209 <--
JP 2006511536	T	20060406	JP 2004-560372	20031209 <--
US 20060263397	A1	20061123	US 2006-494131	20060727 <--
US 20070009559	A1	20070111	US 2006-494129	20060727 <--
PRIORITY APPLN. INFO.:			US 2002-317657	A 20021212 <--
			WO 2003-US38979	W 20031209 <--


ED Entered STN: 17 Jun 2004

AB Disclosed is a free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1-30 % of the drug, 5-60 % of a surfactant, 10-40 % of water; 1-20 % of unsatd. fatty acid ester, 0-50 % water miscible pharmaceutically acceptable polyol and 1-10 % phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixt. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form. A gel composition containing polyoxyethylene sorbitan monooleate 35, propylene glycol 25, Et linoleate 8, simvastatin 4, and 5 % lecithin aqueous solution q.s. to 100 % was formulated. Colloidal silicon dioxide 30 parts was granulated with the obtained gel 70 parts. The granules was dried to provide a free-flowing powder. When this powder was exposed to a gastric medium of pH 1.2, 67 % of the drug simvastatin dissolved within 10 min.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (free-flowing solid formulations with improved bio-availability of  
 poorly water soluble drugs obtained from gel compns. containing  
 surfactants,  
 fatty acid esters, polyols, and phospholipids)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-  
 (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 31 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:287775 HCAPLUS Full-text  
 DOCUMENT NUMBER: 140:309387  
 TITLE: Oral pharmaceutical compositions of fenofibrate having high bioavailability  
 INVENTOR(S): Miriyala, Gowri Shankar; Singla, Ajay Kumar; Malik, Rajiv  
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India; Roy, Sunilendu Bhushan  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028506	A1	20040408	WO 2003-IB4162	20030924 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN 2002DE00961	A	20050121	IN 2002-DE961	20020924 <--
AU 2003263480	A1	20040419	AU 2003-263480	20030924 <--
EP 1553928	A1	20050720	EP 2003-798327	20030924 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
IN 2005DN01508	A	20071130	IN 2005-DN1508	20050415 <--
PRIORITY APPLN. INFO.:			IN 2002-DE961	A 20020924 <--
			WO 2003-IB4162	W 20030924 <--

ED Entered STN: 08 Apr 2004

AB The present invention relates to oral pharmaceutical compns. of fenofibrate having high bioavailability with improved dissoln. and methods for providing the pharmaceutical compns. The oral pharmaceutical composition of fenofibrate include an inert hydro-insol. carrier having one or more one layers that include fenofibrate in a micronized form, one or more hydrophilic polymers, and one or more surfactants. The composition may have a dissoln. profile of at least about 10% in about 5 min, about 20% in about 10 min, about 50% in about 20 min and about 75% in about 30 min, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia in a dissoln. medium constituted by water with 2% by weight of Polysorbate 80 or with 0.025M sodium lauryl sulfate.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin


RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(oral pharmaceutical compns. of fenofibrate having high bioavailability)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl


ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta,\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 32 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1007596 HCAPLUS Full-text

DOCUMENT NUMBER: 140:65183

TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent

INVENTOR(S): Chen, Feng-Jing; Patel, Mahesh V.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Pat. Appl. 2002 32,171.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030235595	A1	20031225	US 2003-397969	20030325 <--
US 6267985	B1	20010731	US 1999-345615	19990630 <--
US 6309663	B1	20011030	US 1999-375636	19990817 <--
US 20010024658	A1	20010927	US 2000-751968	20001229 <--
US 6458383	B2	20021001		
US 20020032171	A1	20020314	US 2001-877541	20010608 <--
US 6761903	B2	20040713		
WO 2004087052	A2	20041014	WO 2004-US9120	20040325 <--

Serial No.:10/582,410

WO 2004087052

A3

20041118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG

PRIORITY APPLN. INFO.:

US 1999-345615 A2 19990630 <--  
US 1999-375636 A2 19990817 <--  
US 2000-751968 A2 20001229 <--  
US 2001-877541 A2 20010608 <--  
WO 2000-US18807 A 20000710 <--  
US 2003-397969 A 20030325 <--

ED Entered STN: 28 Dec 2003

AB The present invention relates to oral pharmaceutical compns. and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compns. of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compns. provided.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(oral composition containing triglyceride and surfactants for improved delivery of hydrophobic drugs)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 42017-89-0, Fenofibric acid


RL: BSU (Biological study, unclassified); BIOL (Biological study)

(plasma concentration of; oral composition containing triglyceride and surfactants for

improved delivery of hydrophobic drugs)

RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



L55 ANSWER 33 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1007351 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:65181

TITLE: Solid pharmaceutical composition containing a lipophilic active ingredient and process for its preparation

INVENTOR(S): Abou Chacra, Vernet Marie Line; Zakarian, Noel; Toselli, Dominique; Gimet, Rene; Laruelle, Claude

PATENT ASSIGNEE(S): CLL Pharma, Fr.

SOURCE: Fr. Demande, 36 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2841138	A1	20031226	FR 2002-7831	20020625 <--
FR 2841138	B1	20050225		
CA 2490341	A1	20031231	CA 2003-2490341	20030624 <--
WO 2004000279	A1	20031231	WO 2003-FR1933	20030624 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

Serial No.:10/582,410

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003260621 A1 20040106 AU 2003-260621 20030624 <--  
 EP 1521574 A1 20050413 EP 2003-760779 20030624 <--  
 EP 1521574 B1 20070307

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005533802 T 20051110 JP 2004-514981 20030624 <--  
 AT 355829 T 20070315 AT 2003-760779 20030624 <--  
 ES 2283821 T3 20071101 ES 2003-760779 20030624 <--  
 ZA 2005000716 A 20060927 ZA 2005-716 20050125 <--  
 US 20080095838 A1 20080424 US 2005-519166 20051026 <--

PRIORITY APPLN. INFO.: FR 2002-7831 A 20020625 <--  
 WO 2003-FR1933 W 20030624 <--

ED Entered STN: 28 Dec 2003

AB A solid oral pharmaceutical composition, comprises a lipophilic active ingredient, a surfactant, a cationic polymer insol. in water at pH equal to or higher than 5, and one mineral or organic acid. Preparation of tablets containing 195 mg fenofibrate are described.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid pharmaceutical composition containing lipophilic active ingredient and process for its preparation)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 34 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757020 HCAPLUS Full-text

DOCUMENT NUMBER: 139:281229

TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of U.S. Ser. No. 800,593.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20030180352	A1	20030925	US 2002-159601	20020530 <--
US 6248363	B1	20010619	US 1999-447690	19991123 <--
US 20030064097	A1	20030403	US 2001-800593	20010306 <--
US 6569463	B2	20030527		

PRIORITY APPLN. INFO.: US 1999-447690 A3 19991123 <--  
US 2001-800593 A2 20010306 <--

ED Entered STN: 26 Sep 2003


AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. For example, beads were prepared containing omeprazole 8.8%, PEG-150 monostearate 27.8%, PEG-40 monostearate 13.9%, Maisine 35-1 4.6%, magnesium carbonate 0.9%, and nonpareil seed (30/35 mesh) 44.1%. The beads were further coated with an enteric coating layer by spraying a Eudragit L100 solution

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid carriers for improved delivery of therapeutic agents)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-

(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 35 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:696722 HCAPLUS Full-text  
 DOCUMENT NUMBER: 139:219350  
 TITLE: Pharmaceutical dosage forms coated with and acrylic copolymers  
 INVENTOR(S): Petereit, Hans-Ulrich; Suefke, Thomas; Meier, Christian; Schnabel, Michael; Blesing, Ingrid; Grimm, Stefan  
 PATENT ASSIGNEE(S): Roehm G.m.b.H. & Co. K.-G., Germany  
 SOURCE: PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072087	A1	20030904	WO 2003-EP934	20030130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10208335	A1	20030904	DE 2002-10208335	20020227 <--
CA 2476972	A1	20030904	CA 2003-2476972	20030130 <--
AU 2003218641	A1	20030909	AU 2003-218641	20030130 <--
EP 1478352	A1	20041124	EP 2003-711870	20030130 <--
EP 1478352	B1	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008006	A	20050104	BR 2003-8006	20030130 <--
JP 2005526546	T	20050908	JP 2003-570833	20030130 <--
AT 336232	T	20060915	AT 2003-711870	20030130 <--
ES 2272955	T3	20070501	ES 2003-711870	20030130 <--
US 20050079216	A1	20050414	US 2004-502648	20040803 <--
IN 2004CN01861	A	20060623	IN 2004-CN1861	20040820 <--

Serial No.:10/582,410

MX 2004PA08344	A	20041126	MX 2004-PA8344	20040827 <--
KR 784657	B1	20071212	KR 2004-713492	20040827 <--
MX 2004PA10956	A	20050125	MX 2004-PA10956	20041105 <--
PRIORITY APPLN. INFO.:			DE 2002-10208335	A 20020227 <--
			WO 2003-EP934	W 20030130 <--
			DE 2003-10319458	A 20030429 <--


ED Entered STN: 05 Sep 2003

AB The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 weight % methacrylic acid, 20 to 69 weight % methylacrylate and 0 to 40 weight % ethylacrylate and, optionally, of 0 to 10 weight % of addnl. vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof. Thus a copolymer was prepared using the monomers: Me acrylate 40; Et acrylate 30; methacrylic acid 30. An emulsion polymerizate containing 30% of the copolymer was mixed with 0.85% sodium lauryl sulfate (in relation to the copolymer); the fluid was dried to a film; the film was soluble in an artificial intestinal juice at pH 6.8.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical dosage forms coated with and acrylic copolymers)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 36 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:633275 HCAPLUS Full-text  
 DOCUMENT NUMBER: 139:169333  
 TITLE: Novel anticholesterol compositions and method for using same  
 INVENTOR(S): Dudley, Robert; Liao, Shutsung; Song, Ching  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030153541	A1	20030814	US 2002-174934	20020619 <--
WO 9922728	A1	19990514	WO 1998-US23041	19981030 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6576660	B1	20030610	US 2000-530443	20000428 <--
US 6645955	B1	20031111	US 2000-560236	20000428 <--
ZA 2001009793	A	20030228	ZA 2001-9793	20011128 <--
CA 2438221	A1	20020815	CA 2002-2438221	20020207 <--
AU 2002238093	A1	20020819	AU 2002-238093	20020207 <--
EP 1385868	A2	20040204	EP 2002-704407	20020207 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508281	T	20050331	JP 2002-562310	20020207 <--
US 20020107233	A1	20020808	US 2002-72128	20020208 <--
US 20020193357	A1	20021219	US 2002-137695	20020502 <--
US 7012069	B2	20060314		
CA 2489702	A1	20031231	CA 2003-2489702	20030619 <--
WO 2004001002	A2	20031231	WO 2003-US19515	20030619 <--
WO 2004001002	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

# Serial No.:10/582,410


LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003245605 A1 20040106 AU 2003-245605 20030619 <--  
 EP 1534298 A2 20050601 EP 2003-739234 20030619 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005533810 T 20051110 JP 2004-516031 20030619 <--  
 PRIORITY APPLN. INFO.: US 1997-63770P P 19971031 <--  
 WO 1998-US23041 W 19981030 <--  
 US 1999-131728P P 19990430 <--  
 US 2000-530443 A2 20000428 <--  
 US 2000-560236 A2 20000428 <--  
 US 2001-267493P P 20010208 <--  
 US 2001-288643P P 20010503 <--  
 US 2001-348020P P 20011108 <--  
 US 2002-72128 A2 20020208 <--  
 US 2002-137695 A2 20020502 <--  
 US 2000-191864P P 20000324 <--  
 WO 2002-US3826 W 20020207 <--  
 US 2002-174934 A 20020619 <--  
 WO 2003-US19515 W 20030619 <--  
 OTHER SOURCE(S): MARPAT 139:169333  
 ED Entered STN: 15 Aug 2003  
 AB Disclosed are compns., methods, combinations, and kits for treating a disorder  
 related to elevated serum cholesterol concentration, for example,  
 atherosclerosis, elevated LDL plasma levels, low HDL plasma levels,  
 hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia,  
 cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The  
 compns., methods, combinations, and kits of the present invention are  
 pharmaceutical compns. comprising at least two of an LXR receptor modulator, a  
 therapeutically effective amount of a catechin, and/or a therapeutically  
 effective amount of a lipid regulating agent, such as a HMG-CoA reductase  
 inhibitor, a fibric acid derivative, niacin, a bile-acid sequestrant, an  
 absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone  
 compound, and an unsatd. omega-3 fatty acid.  
 IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anticholesterol compns. containing LXR modulators and lipid regulating  
 agents)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 37 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:492691 HCAPLUS Full-text  
 DOCUMENT NUMBER: 139:47151  
 TITLE: Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)  
 INVENTOR(S): Davis, Harry R.  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 166,942.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 13  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030119757	A1	20030626	US 2002-247032	20020919 <--
US 20030105028	A1	20030605	US 2002-166942	20020611 <--
US 6982251	B2	20060103		
AU 2007201970	A1	20070524	AU 2007-201970	20070503
AU 2007201970	B2	20080417		
AU 2008201609	A1	20080501	AU 2008-201609	20080410
PRIORITY APPLN. INFO.:			US 2001-323937P	P 20010921 <--
			US 2002-166942	A2 20020611 <--
			US 2000-256875P	P 20001220 <--
			US 2001-23295	A2 20011217 <--
			AU 2006-202618	A3 20060620
			AU 2007-201970	A3 20070503

OTHER SOURCE(S): MARPAT 139:47151

ED Entered STN: 29 Jun 2003

AB The present invention provides methods for treating or preventing vascular inflammation or for reducing blood levels of C-reactive protein by administering at least one sterol absorption inhibitor and/or at least one 5 $\alpha$ -stanol absorption inhibitor. A tablet formulation for a sterol of 5 $\alpha$ -stanol absorption inhibitor is presented as well as preparation of ezetimibe. Patients with primary hypercholesterolemia treated with ezetimibe and simvastatin showed significant reduction of C-reactive protein levels.

IT 134523-00-5, Atorvastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


Serial No.:10/582,410

(HMG-CoA reductase inhibitor; sterol or 5 $\alpha$ -stanol absorption inhibitor for reducing blood levels of C-reactive protein and treating or preventing vascular inflammation)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 49562-28-9, Fenofibrate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(further administering peroxisome proliferator-activated receptor activating; sterol or 5 $\alpha$ -stanol absorption inhibitor for reducing blood levels of C-reactive protein and treating or preventing vascular inflammation)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



L55 ANSWER 38 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:334829 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:343889

TITLE: Novel pharmaceutical compounds containing drugs bound to polypeptides

INVENTOR(S): Picariello, Thomas

PATENT ASSIGNEE(S): New River Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 4662 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 27

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

# Serial No.:10/582,410

WO 2003034980	A2	20030501	WO 2001-US43089	20011114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,				
UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,				
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,				
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				
GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428971	A1	20030501	CA 2001-2428971	20011114 <--
AU 2001298033	A1	20030506	AU 2001-298033	20011114 <--
AU 2001298033	B2	20070809		
EP 1401374	A1	20040331	EP 2001-274606	20011114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2006516948	T	20060713	JP 2003-537549	20011114 <--
US 20040063628	A1	20040401	US 2002-156527	20020529 <--
US 7060708	B2	20060613		
US 20070232529	A1	20071004	US 2004-923088	20040823 <--
US 7427600	B2	20080923		
US 20070060500	A1	20070315	US 2006-392878	20060330 <--
US 20080086016	A1	20080410	US 2007-745019	20070507 <--
AU 2007203485	A1	20070816	AU 2007-203485	20070726 <--
PRIORITY APPLN. INFO.:				
			US 2000-247622P	P 20001114 <--
			US 1999-265415	B2 19990310 <--
			US 1999-411238	B2 19991004 <--
			WO 2000-US5693	A 20000306 <--
			US 2000-642820	A2 20000822 <--
			US 2000-247556P	P 20001114 <--
			US 2000-247558P	P 20001114 <--
			US 2000-247559P	P 20001114 <--
			US 2000-247560P	P 20001114 <--
			US 2000-247561P	P 20001114 <--
			US 2000-247594P	P 20001114 <--
			US 2000-247595P	P 20001114 <--
			US 2000-247606P	P 20001114 <--
			US 2000-247607P	P 20001114 <--
			US 2000-247608P	P 20001114 <--
			US 2000-247610P	P 20001114 <--
			US 2000-247613P	P 20001114 <--
			US 2000-247614P	P 20001114 <--
			US 2000-247615P	P 20001114 <--
			US 2000-247616P	P 20001114 <--
			US 2000-247617P	P 20001114 <--
			US 2000-247620P	P 20001114 <--
			US 2000-247621P	P 20001114 <--
			US 2000-247625P	P 20001114 <--
			US 2000-247626P	P 20001114 <--
			US 2000-247627P	P 20001114 <--
			US 2000-247628P	P 20001114 <--
			US 2000-247629P	P 20001114 <--
			US 2000-247630P	P 20001114 <--
			US 2000-247631P	P 20001114 <--
			US 2000-247632P	P 20001114 <--
			US 2000-247633P	P 20001114 <--
			US 2000-247634P	P 20001114 <--
			US 2000-247635P	P 20001114 <--

Serial No.:10/582,410

US 2000-247684P	P	20001114	<--
US 2000-247698P	P	20001114	<--
US 2000-247699P	P	20001114	<--
US 2000-247700P	P	20001114	<--
US 2000-247701P	P	20001114	<--
US 2000-247702P	P	20001114	<--
US 2000-247798P	P	20001114	<--
US 2000-247799P	P	20001114	<--
US 2000-247800P	P	20001114	<--
US 2000-247801P	P	20001114	<--
US 2000-247802P	P	20001114	<--
US 2000-247803P	P	20001114	<--
US 2000-247804P	P	20001114	<--
US 2000-247805P	P	20001114	<--
US 2000-247807P	P	20001114	<--
US 2000-247832P	P	20001114	<--
US 2000-247833P	P	20001114	<--
US 2000-247926P	P	20001114	<--
US 2000-247927P	P	20001114	<--
US 2000-247930P	P	20001114	<--
US 2000-274622P	P	20001114	<--
US 2000-248528P	P	20001116	<--
US 2000-248529P	P	20001116	<--
US 2000-248530P	P	20001116	<--
US 2000-248531P	P	20001116	<--
US 2000-248532P	P	20001116	<--
US 2000-248533P	P	20001116	<--
US 2000-248535P	P	20001116	<--
US 2000-248536P	P	20001116	<--
US 2000-248537P	P	20001116	<--
US 2000-248538P	P	20001116	<--
US 2000-248539P	P	20001116	<--
US 2000-248540P	P	20001116	<--
US 2000-248620P	P	20001116	<--
US 2000-248662P	P	20001116	<--
US 2000-248663P	P	20001116	<--
US 2000-248685P	P	20001116	<--
US 2000-248713P	P	20001116	<--
US 2000-248714P	P	20001116	<--
US 2000-248715P	P	20001116	<--
US 2000-248716P	P	20001116	<--
US 2000-248717P	P	20001116	<--
US 2000-248721P	P	20001116	<--
US 2000-248722P	P	20001116	<--
US 2000-248723P	P	20001116	<--
US 2000-248724P	P	20001116	<--
US 2000-248725P	P	20001116	<--
US 2000-248726P	P	20001116	<--
US 2000-248727P	P	20001116	<--
US 2000-248728P	P	20001116	<--
US 2000-248729P	P	20001116	<--
US 2000-248730P	P	20001116	<--
US 2000-248731P	P	20001116	<--
US 2000-248732P	P	20001116	<--
US 2000-248733P	P	20001116	<--
US 2000-248737P	P	20001116	<--
US 2000-248738P	P	20001116	<--
US 2000-248748P	P	20001116	<--
US 2000-248764P	P	20001116	<--
US 2000-248765P	P	20001116	<--

Serial No.:10/582,410

US	2000-248767P	P	20001116	<--
US	2000-248768P	P	20001116	<--
US	2000-248769P	P	20001116	<--
US	2000-248770P	P	20001116	<--
US	2000-248771P	P	20001116	<--
US	2000-248772P	P	20001116	<--
US	2000-248774P	P	20001116	<--
US	2000-248776P	P	20001116	<--
US	2000-248777P	P	20001116	<--
US	2000-248778P	P	20001116	<--
US	2000-248779P	P	20001116	<--
US	2000-248782P	P	20001116	<--
US	2000-248783P	P	20001116	<--
US	2000-248787P	P	20001116	<--
US	2000-248794P	P	20001116	<--
US	2000-248795P	P	20001116	<--
US	2000-248796P	P	20001116	<--
US	2000-248797P	P	20001116	<--
US	2000-248833P	P	20001116	<--
US	2001-933708	A2	20010822	<--
US	2001-986426	A2	20011108	<--
AU	2001-298033	A3	20011114	<--
US	2001-987458	B2	20011114	<--
WO	2001-US43089	W	20011114	<--
US	2001-988034	B2	20011116	<--
US	2001-988071	B2	20011116	<--
WO	2001-US43115	B2	20011116	<--
WO	2001-US43117	B2	20011116	<--
US	2002-358381P	P	20020222	<--
US	2002-366258P	P	20020322	<--
US	2002-156527	A2	20020529	<--
WO	2003-US5524	A2	20030224	<--
US	2003-507012P	P	20030930	<--
US	2003-727565	A2	20031205	<--
US	2004-567800P	P	20040505	<--
US	2004-567802P	P	20040505	<--
US	2004-568011P	P	20040505	<--
US	2004-857619	A3	20040601	<--
US	2004-923088	A2	20040823	<--
WO	2004-US32131	A2	20040930	<--

ED Entered STN: 02 May 2003

AB Compns. comprising polypeptides and drugs covalently attached to the polypeptide are disclosed. Also provided is a method for delivery of these drugs to a patient comprising administering to the patient a composition comprising a polypeptide and a drug covalently attached to the polypeptide. Also provided is a method for protecting drugs from degradation comprising covalently attaching them to a polypeptide. Also provided is a method for controlling release of drugs from a composition comprising covalently attaching them to the polypeptide.

IT 49562-28-9DP, Fenofibrate, protein conjugates


134523-00-5DP, Atorvastatin, protein conjugates

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel pharmaceutical compds. containing drugs bound to polypeptides)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 39 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:133112 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:175886

TITLE: Oral pharmaceutical composition containing a combination of PPAR $\alpha$  and HMG-CoA reductase inhibitor

INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe; Sereno, Antonio

PATENT ASSIGNEE(S): Galephar M/F, Belg.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013608	A1	20030220	WO 2002-BE135	20020807 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003013607	A1	20030220	WO 2001-BE147	20010907 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			


Serial No.:10/582,410

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2456732 A1 20030220 CA 2002-2456732 20020807 <--  
AU 2002331468 A1 20030224 AU 2002-331468 20020807 <--  
EP 1414496 A1 20040506 EP 2002-766983 20020807 <--  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
US 20050032878 A1 20050210 US 2004-486219 20040908 <--  
US 20070092567 A1 20070426 US 2006-347822 20060206 <--  
PRIORITY APPLN. INFO.: WO 2001-BE133 W 20010807 <--  
WO 2001-BE147 W 20010907 <--  
WO 2002-BE135 W 20020807 <--  
WO 2003-BE133 A2 20030806 <--  
US 2004-486219 A2 20040908 <--  
ED Entered STN: 21 Feb 2003  
AB Disclosed is an oral pharmaceutical composition containing, in the same  
pharmaceutical form, effective amts. of a HMG-CoA reductase inhibitor  
derivative and of peroxisome proliferator activated receptor- $\alpha$  (PPAR $\alpha$ ),  
especially fenofibrate. Also described is the use of some inactive  
ingredients which allow to improve the dissoln. and/or bioavailability of the  
drugs from the said composition A capsule containing simvastatin 20,  
fenofibrate 200, Gelucire 44/14 350, vitamin E TPGS 20, polyethylene glycol  
6000 30, buthylhydroxyanisol 0.08 mg was prepared  
IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral pharmaceutical composition containing PPAR $\alpha$ , HMG-CoA reductase  
inhibitor, glyceride derivs., and other excipients)  
RN 49562-28-9 HCAPLUS  
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-  
(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 40 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:675771 HCAPLUS Full-text

DOCUMENT NUMBER: 137:206561

TITLE: Controlled-release pharmaceuticals containing fatty esters and a cellulose and nonionic surfactant

INVENTOR(S): Gutierrez-Rocca, Jose; Dunne, Josephine; Rios, Saul A.

PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067852	A2	20020906	WO 2002-US1879	20020122 <--
WO 2002067852	A3	20030220		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20020160041	A1	20021031	US 2001-790239	20010221 <--
US 6524615	B2	20030225		
AU 2002248377	A1	20020912	AU 2002-248377	20020122 <--
US 20030118639	A1	20030626	US 2002-212484	20020805 <--
US 6596308	B2	20030722		
US 20030165562	A1	20030904	US 2003-337233	20030106 <--
PRIORITY APPLN. INFO.:			US 2001-790239	A 20010221 <--
			WO 2002-US1879	W 20020122 <--

ED Entered STN: 08 Sep 2002

AB A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation containing a water-insol. drug, a high melting fatty ester, a low-viscosity oil, a cellulose polymer, and a nonionic surfactant. Thus, a controlled-release capsule formulation contained nifedipine 20.0, Compritol-888 25.0, Methocel K-100 3.0, Labrasol 51.0, and Polysorbate-80 2.0 mg.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled-release pharmaceuticals containing fatty esters and cellulose

and nonionic surfactant)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 41 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:256815 HCAPLUS Full-text

DOCUMENT NUMBER: 136:284466

TITLE: Novel formulations comprising lipid-regulating agents

INVENTOR(S): Patel, Jitendra P.; Sanzgiri, Yeshwant D.; Lipari, John M.; Reinland, Thomas L.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 5 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020040046	A1	20020404	US 2000-524113	20000313 <--
PRIORITY APPLN. INFO.:			US 1999-127136P	P 19990331 <--


ED Entered STN: 05 Apr 2002

AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium. SR soybean oil (24.33 g) was added to a beaker and fenofibrate (0.67 g) was dissolved in it by stirring. Sorbitan monooleate (2.5 g) was added to the beaker and mixed until uniform.

Serial No.:10/582,410


Polysorbate 80 (0.5 g) was then added and mixed until uniform. Finally water (72 g) was added slowly with constant mixing until a uniform emulsion resulted. Pharmacokinetics of 67 mg/day fenofibrate was compared with Lipanthyl 67M in fasted dogs.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(novel formulations comprising lipid-regulating agents)  
RN 49562-28-9 HCAPLUS  
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 42 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:240538 HCAPLUS [Full-text](#)  
DOCUMENT NUMBER: 136:268166  
TITLE: Spray drying process for preparation of fenofibrate compositions  
INVENTOR(S): Pace, Gary; Mishra, Awadhesh K.; Snow, Robert A.;  
Parikh, Indu; Guivarc'h, Pol-Henri  
PATENT ASSIGNEE(S): RTP Pharma Inc., USA  
SOURCE: PCT Int. Appl., 69 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024169	A1	20020328	WO 2001-US12746	20010420 <--

# Serial No.:10/582,410

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2423335	A1	20020328	CA 2001-2423335	20010420 <--
AU 2001062945	A	20020402	AU 2001-62945	20010420 <--
US 20020056206	A1	20020516	US 2001-838593	20010420 <--
US 6696084	B2	20040224		
CA 2440355	A1	20020906	CA 2001-2440355	20010420 <--
WO 2002067901	A1	20020906	WO 2001-US12747	20010420 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001259099	A1	20020912	AU 2001-259099	20010420 <--
AU 2001259099	B2	20051222		
US 20020161032	A1	20021031	US 2001-838583	20010420 <--
US 6534088	B2	20030318		
EP 1322289	A1	20030702	EP 2001-937182	20010420 <--
EP 1322289	B1	20070725		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1361867	A1	20031119	EP 2001-932584	20010420 <--
EP 1361867	B1	20070321		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN 1505502	A	20040616	CN 2001-823164	20010420 <--
CN 1273112	C	20060906		
JP 2004523552	T	20040805	JP 2002-567269	20010420 <--
NZ 525306	A	20041126	NZ 2001-525306	20010420 <--
NZ 527408	A	20050429	NZ 2001-527408	20010420 <--
AU 2001262945	B2	20060202	AU 2001-262945	20010420 <--
AT 357216	T	20070415	AT 2001-932584	20010420 <--
AT 367802	T	20070815	AT 2001-937182	20010420 <--
TW 288000	B	20071011	TW 2001-90109551	20010420 <--
ES 2284646	T3	20071116	ES 2001-932584	20010420 <--
US 20040086571	A1	20040506	US 2003-388597	20030317 <--
HK 1061357	A1	20071102	HK 2004-102918	20040426 <--
AU 2007201953	A1	20070524	AU 2007-201953	20070501 <--

PRIORITY APPLN. INFO.:

US 2000-234186P	P	20000920 <--
US 2000-241761P	P	20001020 <--
US 2001-270157P	P	20010222 <--
AU 2001-55515	T0	20010420 <--
US 2001-838583	A3	20010420 <--
WO 2001-US12746	W	20010420 <--
WO 2001-US12747	W	20010420 <--

ED Entered STN: 28 Mar 2002

AB The present invention relates to a novel spray drying process for the preparation of pharmaceutical compns. containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray

dried powdered compns. prepared according to this process and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compns. The powdered compns. and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally. An admixt. of 3% Lipoid E80 as the surfactant and 10% fenofibrate is homogeneously dispersed in pH 8.0 10 mM aqueous phosphate buffer by using a high-shear mixer for 30 min. Mannitol (10%) is then added and the admixt. is heated to 95° during continuous high shear mixing. The heated suspension is then homogenized for 10 batch volume cycles or passes by using a microfluidizer to form a heated homogenate containing the drug. After 10 passes, the heated homogenate is then spray dried to produce a dried powder containing Lipoid E80-stabilized microparticles of fenofibrate in mannitol.


IT 49562-28-9, Fenofibrate

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(spray drying for preparation of fenofibrate compns.)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(spray drying for preparation of fenofibrate compns.)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 43 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:489854 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 135:97449

Serial No.:10/582,410

TITLE: Novel formulations comprising lipid-regulating agents  
 INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010006658	A1	20010705	US 1999-283083	19990331 <--
US 6719999	B2	20040413		

PRIORITY APPLN. INFO.: US 1999-283083 19990331 <--

ED Entered STN: 06 Jul 2001


AB The present invention is directed to a formulation comprising a lipid-regulating agent, e.g., fenofibrate, pravastatin and atorvastatin, dissolved in one or more non-aqueous and/or water-miscible solvents, e.g., ethanol, or optionally, in a premix of one or more solvents and one or more surfactants, such as, Labrafac Lipophile WL 1349, Lauroglycol FCC, Labrafil M 1944, Span 80, sorbitan oleate, etc. A hypolipemic liquid composition is filled into capsules. For example, pravastatin (5.0 g) was mixed with di-Me isosorbide (25 g) until dissolved. Labrafac Lipophile WL 1349 (25 g) is added to the solution. Mixing is continued until a clear solution is obtained. Appropriate amount of solution may be filled into capsules to provide the desired dose.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(capsule formulations comprising dissolved hypolipemic drug and surfactant)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 44 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:396644 HCAPLUS Full-text

DOCUMENT NUMBER: 135:24671

TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123 <--
CA 2391923	A1	20010531	CA 2000-2391923	20001122 <--
EP 1233756	A1	20020828	EP 2000-980761	20001122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517470	T	20030527	JP 2001-539423	20001122 <--
PRIORITY APPLN. INFO.:			US 1999-447690	A 19991123 <--
			WO 2000-US32255	W 20001122 <--

ED Entered STN: 01 Jun 2001

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and

Serial No.:10/582,410


triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 45 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:900426 HCAPLUS Full-text

DOCUMENT NUMBER: 134:46814

TITLE: Novel formulations comprising lipid-regulating agents containing fibrate and statin

INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2000076482	A1	20001221	WO 2000-US15717	20000608 <--
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 20010007670	A1	20010712	US 1999-330589	19990611 <--
US 6372251	B2	20020416		
CA 2376217	A1	20001221	CA 2000-2376217	20000608 <--
EP 1185252	A1	20020313	EP 2000-938209	20000608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003520772	T	20030708	JP 2001-502816	20000608 <--
MX 2001PA12778	A	20020918	MX 2001-PA12778	20011211 <--
PRIORITY APPLN. INFO.:			US 1999-330589	A 19990611 <--
			WO 2000-US15717	W 20000608 <--

ED Entered STN: 22 Dec 2000


AB The present invention is directed to a semi-solid formulation comprising a lipid-regulating agent, i.e. fibrate or statin. The formulation is prepared by solubilizing the lipid-regulating agent such as fenofibrate, pravastatin, or atorvastatin in one or more liquid components to form a clear liquid solution, then solidifying the solution by adding one or more solid or semi-solid components such as Cremophor RH40 or PEG to the solution to form a semi-solid formulation. The formulation can melt or dissolve upon mixing with a bulk aqueous medium. The resulting formulation results in an increase in drug solubility and oral bioavailability, and an improved dissoln. rate.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (oral semisolid dosage forms containing lipid-regulating agents)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 46 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:861475 HCAPLUS Full-text  
 DOCUMENT NUMBER: 134:32974  
 TITLE: Novel formulations comprising lipid-regulating agents  
 INVENTOR(S): Law, Devalina; Krill, Steven L.; Schmitt, Eric A.; Fort, James J.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 16 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072829	A1	20001207	WO 2000-US14109	20000523 <--
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2374117	A1	20001207	CA 2000-2374117	20000523 <--
EP 1183017	A1	20020306	EP 2000-937680	20000523 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003500439	T	20030107	JP 2000-620941	20000523 <--
MX 2001PA12225	A	20020812	MX 2001-PA12225	20011128 <--
PRIORITY APPLN. INFO.:			US 1999-323183	A 19990528 <--
			WO 2000-US14109	W 20000523 <--

ED Entered STN: 08 Dec 2000


AB The present invention is directed to a solid formulation comprising the mixture of a lipid-regulating agent and an excipient, in which the agent and the excipient form a eutectic mixture. Thus, fenofibrate and PEG (15:85) was heated to 85° until a clear solution was obtained. The solution was cooled to get a solid mass, which was ground and sieved through a 600-100 mesh screen. The solid was filled into capsules.

IT 42017-89-0, Fenofibric acid

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (formulations comprising lipid-regulating agents)


RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)




IT 49562-28-9, FenoFibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (formulations comprising lipid-regulating agents)

RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 47 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:861472 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 134:32971  
 TITLE: Novel formulations comprising lipid-regulating agents  
 INVENTOR(S): Law, Devalina; Krill, Steven L.; Schmitt, Eric A.; Fort, James J.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072825	A1	20001207	WO 2000-US14106	20000523 <--
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 20010006662	A1	20010705	US 1999-320188	19990529 <--
US 6465011	B2	20021015		
CA 2374288	A1	20001207	CA 2000-2374288	20000523 <--
EP 1183012	A1	20020306	EP 2000-932706	20000523 <--

Serial No.:10/582,410

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 2003500437	T	20030107	JP 2000-620937	20000523 <--
MX 2001PA12162	A	20020722	MX 2001-PA12162	20011127 <--
PRIORITY APPLN. INFO.:			US 1999-320188	A 19990529 <--
			WO 2000-US14106	W 20000523 <--


ED Entered STN: 08 Dec 2000

AB The present invention is directed to a solid formulation comprising the lipid-regulating agent dispersed in a hydrophilic, amorphous polymer in which the lipid-regulating agent is present as a metastable, amorphous phase. A mixture of fenofibrate and PVP (15:85) was dissolved in EtOH. The EtOH was evaporated and the solid mass was ground and sieved through a 60-100 mesh screen and the resulting granular formulation was filled into individual capsules.

IT 42017-89-0, Fenofibric acid 49562-28-9, Fenofibrate  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (formulations comprising lipid-regulating agents)


RN 42017-89-0 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl- (CA INDEX NAME)



RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




IT 134523-00-5, Atorvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (formulations comprising lipid-regulating agents)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 48 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:707019 HCAPLUS Full-text  
 DOCUMENT NUMBER: 133:271719  
 TITLE: Novel formulations comprising lipid-regulating agents  
 INVENTOR(S): Liu, Rong; Pan, Qinghai; Hansrani, Pawan  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057918	A2	20001005	WO 2000-US7459	20000321 <--
WO 2000057918	A3	20010118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367995	A1	20001005	CA 2000-2367995	20000321 <--
EP 1165141	A2	20020102	EP 2000-919496	20000321 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540174	T	20021126	JP 2000-607667	20000321 <--
MX 2001PA09839	A	20020621	MX 2001-PA9839	20010928 <--
PRIORITY APPLN. INFO.:				
			US 1999-283356	A 19990331 <--
			WO 2000-US7459	W 20000321 <--

ED Entered STN: 06 Oct 2000

AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in a mixture of an oil and one or more surfactants to form a concentrate. This concentrate forms fine and stable emulsions upon gentle mixing with water or any aqueous solns. Distillated acetylated monoglyceride (Myvacet 9-08) was mixed with propylene glycol laurate. Fenofibrate was then added to the mixture and mixed until completely dissolved. One drop of the solution was diluted with 10 mL of water to obtain a soft gelatin capsule.

IT 49562-28-9, Fenofibrate


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(lipid-regulating emulsions containing active agents and surfactants and oils)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lipid-regulating emulsions containing active agents and surfactants and oils)

RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 49 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:706964 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 133:271710

TITLE: Novel formulations comprising lipid-regulating agents

INVENTOR(S): Patel, Jitendra P.; Sanzgiri, Yeshwant D.; Lipari, John M.; Reiland, Thomas L.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057859	A1	20001005	WO 2000-US7650	20000323 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				


Serial No.:10/582,410

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2365128 A1 20001005 CA 2000-2365128 20000323 <--  
 EP 1162954 A1 20011219 EP 2000-919545 20000323 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2003520767 T 20030708 JP 2000-607610 20000323 <--  
 MX 2001PA09840 A 20020621 MX 2001-PA9840 20010928 <--  
 PRIORITY APPLN. INFO.: US 1999-282513 A 19990331 <--  
 WO 2000-US7650 W 20000323 <--  
 ED Entered STN: 06 Oct 2000  
 AB The present invention is directed to a formulation comprising a lipid-  
 regulating agent dissolved or dispersed in at least one oil and an emulsifier  
 or emulsifier blend, the resulting mixture being capable of forming an  
 emulsion upon dilution in an aqueous medium. The emulsions result in an  
 increase in drug solubility, oral bioavailability, and half-life. Pravastatin  
 1 g was dispersed in 24 g soybean oil and 2.5 g sorbitan monooleate, 0.5 g  
 Polysorbate 80, and 72 g water were added with constant mixing until a uniform  
 emulsion resulted.  
 IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (stable emulsions containing hypolipemics)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-  
 (1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-  
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

L55 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:441608 HCAPLUS Full-text  
 DOCUMENT NUMBER: 133:63989  
 TITLE: Novel formulations comprising lipid-regulating agents  
 INVENTOR(S): Lipari, John M.; Raymond, Dawn M.; Reiland, Tom  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037057	A2	20000629	WO 1999-US29696	19991215 <--
WO 2000037057	A3	20001116		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2355820	A1	20000629	CA 1999-2355820	19991215 <--
EP 1140036	A2	20011010	EP 1999-967317	19991215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002532539	T	20021002	JP 2000-589168	19991215 <--
PRIORITY APPLN. INFO.:			US 1998-216448	A 19981218 <--
			WO 1999-US29696	W 19991215 <--


ED Entered STN: 30 Jun 2000

AB The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one propylene glycol fatty acid ester as the primary solvent medium for the agent. One or more emulsifiers may be added to the formulation. Capmul PG8 (propylene glycol mono- and dicaprylate from Abitec) 8.3 g was mixed with 1 g Cremophor EL. Fenofibrate 0.7 g was then added to the above mixture. The mixture was added to soft gelatin capsules using a syringe and the capsules were heat-sealed to give capsules containing 67 mg fenofibrate each.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (capsules containing lipid-regulating agents dissolved in propylene glycol fatty acid esters)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-

(CA INDEX NAME)


Absolute stereochemistry.



L55 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:193844 HCAPLUS Full-text  
 DOCUMENT NUMBER: 130:227739  
 TITLE: Method for lowering serum lipid levels employing an  
 MTP inhibitor in combination with another cholesterol  
 lowering drug  
 INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John  
 R., II  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: U.S., 22 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5883109	A	19990316	US 1997-854311	19970512 <--
PRIORITY APPLN. INFO.:			US 1997-854311	19970512 <--


OTHER SOURCE(S): MARPAT 130:227739  
 ED Entered STN: 25 Mar 1999  
 AB A method is provided for lowering serum lipids, cholesterol and/or  
 triglycerides and thereby inhibiting atherosclerosis by administering to a  
 patient an MTP inhibitor, in combination with a cholesterol lowering drug,  
 such as pravastatin. Capsules were prepared containing about 5 mg MTP  
 inhibitor BMS 201,038.  
 IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lowering serum lipid levels employing an MTP inhibitor in combination  
 with another cholesterol lowering drug)  
 RN 49562-28-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
 ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ )-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:113552 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 130:173009

TITLE: Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia

INVENTOR(S): Bova, David J.; Dunne, Josephine

PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906046	A1	19990211	WO 1998-US15989	19980731 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20010006644	A1	20010705	US 1997-903871	19970731 <--
CA 2297764	A1	19990211	CA 1998-2297764	19980731 <--
CA 2297764	C	20060110		
AU 9886800	A	19990222	AU 1998-86800	19980731 <--
EP 1003515	A1	20000531	EP 1998-938227	19980731 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9815549	A	20040622	BR 1998-15549	19980731 <--
NZ 525486	A	20051028	NZ 1998-525486	19980731 <--
EP 1743644	A1	20070117	EP 2006-17425	19980731 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,				

Serial No.:10/582,410

NL, PT, SE  
 EP 1743630 A2 20070117 EP 2006-17607 19980731 <--  
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,  
 NL, PT, SE  
 NO 2000000407 A 20000316 NO 2000-407 20000127 <--  
 AU 2002300546 A1 20030213 AU 2002-300546 20020813 <--  
 AU 2002300546 B2 20060223  
 US 20050255158 A1 20051117 US 2005-71099 20050105 <--  
 PRIORITY APPLN. INFO.: US 1997-903871 A 19970731 <--  
 AU 1998-86800 A3 19980731 <--  
 EP 1998-938227 A3 19980731 <--  
 WO 1998-US15989 W 19980731 <--

ED Entered STN: 19 Feb 1999

AB The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl Me cellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals.


IT 49562-28-9, Fenofibrate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral dosage forms containing HMG-CoA reductase inhibitors and nicotinate and lipid-altering agents for treating hyperlipidemia)


RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



IT 134523-00-5, Atorvastatin  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral dosage forms containing HMG-CoA reductase inhibitors and nicotinate for treating hyperlipidemia)  
 RN 134523-00-5 HCAPLUS  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:113543 HCAPLUS Full-text  
 DOCUMENT NUMBER: 130:187186  
 TITLE: Pharmaceutical composition containing combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds for treating hyperlipidemia once a day at night  
 INVENTOR(S): Bova, David J.; Dunne, Josephine  
 PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906035	A2	19990211	WO 1998-US15990	19980731 <--
WO 9906035	A3	19990422		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2298549	A1	19990211	CA 1998-2298549	19980731 <--

Serial No.:10/582,410

CA 2298549	C	20060110		
AU 9886801	A	19990222	AU 1998-86801	19980731 <--
AU 752673	B2	20020926		
EP 1017390	A2	20000712	EP 1998-938228	19980731 <--
EP 1017390	B1	20070418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
BR 9815548	A	20001107	BR 1998-15548	19980731 <--
JP 2001511444	T	20010814	JP 2000-504849	19980731 <--
NZ 520176	A	20050225	NZ 1998-520176	19980731 <--
AT 359785	T	20070515	AT 1998-938228	19980731 <--
EP 1792616	A1	20070606	EP 2007-3276	19980731 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ES 2283067	T3	20071016	ES 1998-938228	19980731 <--
NO 2000000439	A	20000322	NO 2000-439	20000127 <--
AU 2002313846	A1	20030403	AU 2002-313846	20021205 <--
US 20040053975	A1	20040318	US 2003-260027	20030902 <--
PRIORITY APPLN. INFO.:			US 1997-903752	A 19970731 <--
			AU 1998-86801	A3 19980731 <--
			EP 1998-938228	A3 19980731 <--
			WO 1998-US15990	W 19980731 <--

ED Entered STN: 19 Feb 1999

AB Solid pharmaceutical combinations for oral administration comprise nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release composition for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a composition for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl methylcellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an HMG-CoA reductase inhibitor in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals. A sustained-release tablet contained lovastatin 10.0, methocel E5 29.1, Pluracol E1450 0.9, and niacin 750 mg. The efficacy of the composition in lowering lipids profiles of patients over 43 wk is reported.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pharmaceutical composition containing combinations of HMG-CoA reductase

Serial No.:10/582,410

inhibitors and nicotinic acid compds. for treating hyperlipidemia once  
day at night)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl  
ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(  
(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )-  
(CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:509103 HCAPLUS Full-text

DOCUMENT NUMBER: 129:156944

ORIGINAL REFERENCE NO.: 129:31837a,31840a

TITLE: Method for treating acid lipase deficiency diseases  
with a microsomal triglyceride transfer protein (MTP)  
inhibitor and cholesterol lowering drug

INVENTOR(S): Gregg, Richard E.; Wetterau, John R., II

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831367	A1	19980723	WO 1998-US619	19980113 <--
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

Serial No.:10/582,410

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
GA, GN, ML, MR, NE, SN, TD, TG

US 6066653 A 20000523 US 1998-5437 19980110 <--  
AU 9861315 A 19980807 AU 1998-61315 19980113 <--  
PRIORITY APPLN. INFO.: US 1997-36183P P 19970117 <--  
WO 1998-US619 W 19980113 <--

OTHER SOURCE(S): MARPAT 129:156944

ED Entered STN: 17 Aug 1998

AB A method is provided for inhibiting or treating diseases associated with acid lipase deficiency by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acid lipase deficiency disease treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R, \delta R$ ) - (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:509064 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:144862

ORIGINAL REFERENCE NO.: 129:29419a,29422a

TITLE: Method for treating or inhibiting phytosterolemia with

Serial No.:10/582,410

a microsomal triglyceride transfer protein (MTP)  
inhibitor and cholesterol lowering drug

INVENTOR(S): Gregg, Richard E.  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA  
SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831225	A1	19980723	WO 1998-US618	19980113 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6057339	A	20000502	US 1998-5430	19980110 <--
AU 9860232	A	19980807	AU 1998-60232	19980113 <--
PRIORITY APPLN. INFO.:			US 1997-35591P	P 19970117 <--
			WO 1998-US618	W 19980113 <--

OTHER SOURCE(S): MARPAT 129:144862

ED Entered STN: 17 Aug 1998

AB A method is provided for inhibiting onset or treating phytosterolemia by administering to a patient an MTP inhibitor, alone or, optionally, in combination with another cholesterol lowering drug, e.g. pravastatin.


IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phytosterolemia treatment with microsomal triglyceride transfer protein inhibitor and cholesterol lowering drug)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:87580 HCAPLUS Full-text

DOCUMENT NUMBER: 128:162883

ORIGINAL REFERENCE NO.: 128:31931a,31934a

TITLE: Method for lowering serum lipid levels employing a microsomal triglyceride-transfer protein (MTP) inhibitor in combination with another cholesterol-lowering drug

INVENTOR(S): Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803069	A1	19980129	WO 1997-US12229	19970714 <--
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9705950	A	19990104	ZA 1997-5950	19970703 <--
CA 2260995	A1	19980129	CA 1997-2260995	19970714 <--
AU 9736624	A	19980210	AU 1997-36624	19970714 <--
AU 716145	B2	20000217		
EP 1014791	A1	20000705	EP 1997-933435	19970714 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2000515526	T	20001121	JP 1998-507023	19970714 <--
PRIORITY APPLN. INFO.:			US 1996-22866P	P 19960724 <--
			WO 1997-US12229	W 19970714 <--

OTHER SOURCE(S): MARPAT 128:162883

ED Entered STN: 14 Feb 1998

AB A method is provided for lowering serum lipids, cholesterol, and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor in combination with a cholesterol lowering drug, e.g. pravastatin.

IT 49562-28-9, Fenofibrate 134523-00-5, Atorvastatin


Serial No.:10/582,410

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(microsomal triglyceride-transfer protein (MTP) inhibitor combination with cholesterol-lowering drug for lowering serum lipid level)

RN 49562-28-9 HCAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 134523-00-5 HCAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta,\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta R,\delta R$ )- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## Search History

```

L1          1 SEA ABB=ON  PLU=ON  US2006-582410/APPS

FILE 'REGISTRY' ENTERED AT 08:14:06 ON 18 NOV 2008
L2          53 SEA ABB=ON  PLU=ON  (102-71-6/BI OR 106392-12-5/BI OR 1066-33-7
          /BI OR 107-15-3/BI OR 111-42-2/BI OR 11137-98-7/BI OR 1305-62-0
          /BI OR 1309-42-8/BI OR 1310-58-3/BI OR 1310-65-2/BI OR
          1310-73-2/BI OR 1330-43-4/BI OR 1336-21-6/BI OR 1343-88-0/BI
          OR 134523-00-5/BI OR 134523-03-8/BI OR 141-43-5/BI OR 144-55-8/
          BI OR 147511-69-1/BI OR 14807-96-6/BI OR 24758-59-6/BI OR
          25013-16-5/BI OR 25322-68-3/BI OR 287714-41-4/BI OR 39366-43-3/
          BI OR 471-34-1/BI OR 49562-28-9/BI OR 497-19-8/BI OR 50-81-7/BI
          OR 515-98-0/BI OR 546-93-0/BI OR 557-04-0/BI OR 56-87-1/BI OR
          6284-40-8/BI OR 63-42-3/BI OR 69-65-8/BI OR 74811-65-7/BI OR
          75330-75-5/BI OR 7664-41-7/BI OR 77-86-1/BI OR 77-92-9/BI OR
          7757-93-9/BI OR 7758-87-4/BI OR 7783-28-0/BI OR 79902-63-9/BI
          OR 81093-37-0/BI OR 874114-41-7/BI OR 9004-34-6/BI OR 9004-64-2
          /BI OR 9005-25-8/BI OR 9005-65-6/BI OR 9028-35-7/BI OR
          93957-54-1/BI)
L3          STRUCTURE UPLOADED
L4          50 SEA SSS SAM L3
L5          4 SEA ABB=ON  PLU=ON  L2 AND N=1 AND O=3
          D SCAN
L6          1 SEA ABB=ON  PLU=ON  "1,3-PROPANEDIOL, 2-AMINO-2-(HYDROXYMETHYL)
          -"/CN
L7          2 SEA ABB=ON  PLU=ON  L2 AND N=2 AND O=5 AND NR=4
L8          1204 SEA ABB=ON  PLU=ON  77-86-1/CRN
L9          1 SEA ABB=ON  PLU=ON  "1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPH
          ENYL)-B, $\Delta$ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((P
          HENYLAMINO)CARBONYL)-, (BR, $\Delta$ R)-"/CN
          SEL RN
L10         131 SEA ABB=ON  PLU=ON  134523-00-5/CRN
L11         1 SEA ABB=ON  PLU=ON  L2 AND O=4 AND NR=2 AND CL=1
          E "PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYL-, 1-
L12         1 SEA ABB=ON  PLU=ON  "PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHEN
          OXY)-2-METHYL-, 1-METHYLETHYL ESTER"/CN
          SEL RN
L13         17 SEA ABB=ON  PLU=ON  49562-28-9/CRN

FILE 'HCAPLUS' ENTERED AT 08:36:35 ON 18 NOV 2008
L14         10674 SEA ABB=ON  PLU=ON  (L6 OR L8)
L15         4140 SEA ABB=ON  PLU=ON  (L9 OR L10)
L16         1868 SEA ABB=ON  PLU=ON  (L12 OR L13)
L17         9 SEA ABB=ON  PLU=ON  L14 AND L15 AND L16
L18         1 SEA ABB=ON  PLU=ON  L17 AND L1

FILE 'BIOSIS, EMBASE, DRUGU, MEDLINE, TOXCENTER' ENTERED AT 10:31:04 ON
18 NOV 2008
L19         12476 SEA ABB=ON  PLU=ON  (L6 OR L8)
L20         18785 SEA ABB=ON  PLU=ON  (L9 OR L10)
L21         9094 SEA ABB=ON  PLU=ON  (L12 OR L13)
L22         8 SEA ABB=ON  PLU=ON  L19 AND L20 AND L21
L23         1535 SEA ABB=ON  PLU=ON  L15 AND L16
L24         1527 SEA ABB=ON  PLU=ON  L23 NOT L19

```

FILE 'REGISTRY' ENTERED AT 10:36:15 ON 18 NOV 2008

Serial No.:10/582,410

L25           0 SEA ABB=ON   PLU=ON   L4 AND L2  
L26           2792 SEA SSS FUL L3  
L27           4 SEA ABB=ON   PLU=ON   L2 AND L26

FILE 'HCAPLUS' ENTERED AT 10:39:43 ON 18 NOV 2008

L28           406 SEA ABB=ON   PLU=ON   HOLM P?/AU  
L29           32 SEA ABB=ON   PLU=ON   NORLING T?/AU  
L30           1 SEA ABB=ON   PLU=ON   (L28 OR L29) AND L17

FILE 'BIOSIS, EMBASE, DRUGU, MEDLINE, TOXCENTER' ENTERED AT 10:42:09 ON  
18 NOV 2008

L31           0 SEA ABB=ON   PLU=ON   (L28 OR L29) AND L22

FILE 'REGISTRY' ENTERED AT 12:30:21 ON 18 NOV 2008

L32           STRUCTURE UPLOADED  
L33           50 SEA SUB=L26 SSS SAM L32  
L34           1370 SEA SUB=L26 SSS FUL L32  
L35           STRUCTURE UPLOADED  
L36           13 SEA SUB=L26 SSS SAM L35  
L37           321 SEA SUB=L26 SSS FUL L35  
L38           STRUCTURE UPLOADED  
L39           1104 SEA SUB=L26 SSS FUL L38

FILE 'HCAPLUS' ENTERED AT 12:33:48 ON 18 NOV 2008

L40           9 SEA ABB=ON   PLU=ON   L34 AND L37 AND L39  
L41           2 SEA ABB=ON   PLU=ON   L37(L)L39  
L42           347 SEA ABB=ON   PLU=ON   L37 AND L39  
L43           250 SEA ABB=ON   PLU=ON   L42 AND (PRY<=2005 OR AY<=2005 OR PY<=2005)

L44           1 SEA ABB=ON   PLU=ON   (L28 OR L29) AND L17  
L45           1 SEA ABB=ON   PLU=ON   (L30 OR L44)  
L46           152 SEA ABB=ON   PLU=ON   L43 AND 63/SC, SX  
L47           243067 SEA ABB=ON   PLU=ON   DRUG DELIVERY SYSTEMS+NT/CT  
L48           111 SEA ABB=ON   PLU=ON   L46 AND L47  
L49           49418 SEA ABB=ON   PLU=ON   DRUG DELIVERY SYSTEMS+NT/CT(L) (CAPSULE/OBI  
OR SACHET/OBI OR TABLET/OBI)  
L50           60 SEA ABB=ON   PLU=ON   L46 AND L49

FILE 'HCAPLUS' ENTERED AT 12:52:12 ON 18 NOV 2008

L51           1 DUP REM L45 L31 (0 DUPLICATES REMOVED)

FILE 'HCAPLUS' ENTERED AT 12:52:28 ON 18 NOV 2008

L52           8 SEA ABB=ON   PLU=ON   L17 NOT L45

FILE 'BIOSIS, EMBASE, MEDLINE, TOXCENTER, DRUGU' ENTERED AT 12:52:55 ON  
18 NOV 2008

L53           8 SEA ABB=ON   PLU=ON   L22 NOT L31

FILE 'HCAPLUS, TOXCENTER' ENTERED AT 12:53:19 ON 18 NOV 2008

L54           9 DUP REM L52 L53 (7 DUPLICATES REMOVED)

FILE 'HCAPLUS' ENTERED AT 12:54:17 ON 18 NOV 2008

L55           56 SEA ABB=ON   PLU=ON   L50 NOT (L45 OR L52 OR L53)